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1 Summary
Diminished mitochondrial function impacts on cellular metabolism but also critically
inﬂuences life and also health span. Mitochondrial dysfunction due to accumulating
mitochondrial damage is considered one of the main factors of aging and aging-related
disease such as Alzheimer's disease and other neurodegenerative disorders. Mitochondrial
quality control is essential to prevent dysfunction and associated deleterious outcomes.
Multi-tiered molecular machinery is in place to remove and degrade superﬂuous or dam-
aged proteins to maintain mitochondrial proteostasis, cull mitochondrial subunits beyond
repair or remove entire mitochondrial networks through apoptosis. Besides proteolytic
pathways, autophagic removal is an important part of mitochondrial quality control.
Severe damage to mitochondria exceeding the repair capacity of proteolytic systems,
but below the apoptotic threshold, leads to the removal of mitochondrial units through
mitochondria-speciﬁc autophagy or mitophagy under control of the kinase PINK1 and
the ubiquitin ligase Parkin. Following recognition of damaged mitochondrial subunits by
PINK1, Parkin is recruited causing the ubiquitination of mitochondrial proteins. This
results in the recruitment of autophagy cargo adaptors leading to the engulfment of
the damaged mitochondria and its subsequent degradation in the lysosome. Among the
proteins recruited during mitophagy is the AAA-ATPase VCP/p97. As ubiquitously
expressed protein, p97 acts in a plethora of cellular functions involving ubiquitination,
including cell cycle control, transcriptional regulation as well as proteostasis. In addition,
p97 was recently connected to ubiquitin-mediated degradation of mitochondrial proteins,
Parkin-dependent mitophagy and deubiquitinating enzymes. These multiple diverse func-
tions of p97 suggest tight spatial and temporal control of its activity, which is brought
upon by the interaction with various cofactors promoting substrate recognition and pro-
cessing by p97.
In this in vitro study the connection of p97 to mitochondrial quality control with focus
on mitophagy was studied. In a ﬁrst step, p97 cofactors were screened using subcellular
localization analysis for their ability to translocate to mitochondria under mitophagic
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conditions. From this screen, UBXD1, SAKS1, and Erasin were found to alter their
locations following mitophagic induction implicating these proteins in the autophagic
clearance of mitochondria. Further analysis suggested a role for UBXD1 as recruitment
factor for p97 to damaged mitochondria. It was shown that UBXD1 recognizes depolar-
ized mitochondria via its C-terminal UBX domain and translocates to mitochondria in
a Parkin-dependent manner. Once translocated, UBXD1 recruits p97 to mitochondria
via a bipartite binding motif consisting of its N-terminal VIM and PUB domains. Re-
cruitment of p97 by UBXD1 only depends on the presence of UBXD1 on mitochondria
without the need for further mitochondrial signals. Following translocation of UBXD1
to CCCP-depolarized mitochondria and p97 recruitment, formation of autolysosomes is
strongly enhanced and autophagic degradation of mitochondria is signiﬁcantly acceler-
ated. Diminished levels of UBXD1 result in decreased mitophagic ﬂux.
In a next step, a potential role in mitophagy for the deubiquitinating enzyme YOD1 was
studied. YOD1 was previously reported to facilitate together with p97 and UBXD1
lyosphagy and ERAD. Alternative transcript analysis revealed a diﬀerential role for
YOD1. Under mitophagic conditions, the shorter YOD1.2 was translocating to mito-
chondrial while the longer YOD1.1 remained in the cytosol. In addition, ecotopic expres-
sion of UBXD1 greatly enhanced mitochondrial translocation of YOD1.2. Under these
conditions, UBXD1 and YOD1.2 translocate to depolarized mitochondria in a mutually
exclusive manner with YOD1.2 seemingly to displace UBXD1.
In summary, the work presented here suggests a novel role for UBXD1 as sensor for
mitochondria undergoing mitophagy and mitochondrial recruitment factor for p97 dur-
ing mitophagy. Furthermore, UBXD1 potentially initiates a multi-step cascade involving
YOD1.2 ultimately aiding the mitophagic quality control of damaged mitochondria.
2
2 Aims of the thesis
 Identiﬁcation of p97 cofactors potentially involved in mitophagy
 Cloning of p97 cofactors into mammalian expression vectors
 Subcellular localization under normal and mitophagic conditions
 Characterization of p97 cofactor UBXD1
 Parkin dependency of UBXD1 mitochondrial translocation
 Structure-function relationship for mitochondrial translocation
 Structure-function relationship for p97 recruitment to mitochondria
 Mitophagic ﬂux under elevated/diminished levels of UBXD1
 Analysis of potential mitophagic role for YOD1
 Subcellular localization of YOD1 during mitophagy
 Structure-function relationship for mitochondrial translocation
 Interplay between YOD1 and UBXD1 under mitophagic conditions
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3 Introduction
3.1 Mitochondria
3.1.1 Mitochondrial structure and function
Mitochondria are multifunctional organelles in eukaryotic cells. Although mostly recog-
nized as powerhouses because of their respiratory energy conversion, mitochondria per-
form various other essential functions. Mitochondria provide ironsulfur cluster assembly,
integrate anabolic and catabolic processes, including amino acid and lipid metabolism,
and participate in cellular ion homeostasis and signalling pathways [1, 2, 3]. Their in-
volvement in cellular metabolism makes mitochondria crucial even for eukaryotes that
inhabit anaerobic environments, with only one recent example of the evolutionary loss
of this organelle [4]. The perturbation of mitochondrial function results in cellular stress
and often has devastating eﬀects, including mitochondrion-related diseases in humans [3].
Mitochondria possess well-deﬁned boundaries that are provided by two membranes that
outline the organelle [5]. These membranes, external or outer mitochondrial membrane
(OMM) and internal or inner mitochondrial membrane (IMM), surround two distinct
aqueous subcompartments: the mitochondrial intermembrane space (IMS) and the mito-
chondrial matrix. The IMM is further divided into an inner boundary membrane that is
adjacent to the OMM and is separated by crista junctions from invaginations that pro-
trude into the matrix, called cristae. Mitochondria are organized into a dynamic network
that is shaped by frequent fusion and ﬁssion processes [6, 7, 8].
To perform their functions, mitochondria need a set of proteins to build the mitochondrial
proteome. The best-characterized proteomes of yeast and human mitochondria comprise
approximately 10001500 diﬀerent proteins, but the annotation of mitochondrial proteins
is an ongoing process [8, 9]. Mitochondria have their own genome and transcription and
translation machinery [10, 11]. However, only a very limited number of mitochondrial
proteins, peptides and ribonucleic acids (RNAs) are synthesized inside the organelle. The
majority of mitochondrial components is produced outside of mitochondria and imported
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using sophisticated import machinery.
Given the overarching importance of mitochondria, impaired mitochondrial homeostasis
and function has been linked to multiple human diseases including cancer and neurode-
generation, but also aging. Their important role, but also their susceptibility to damage,
is mirrored in a multi-layered quality control system keeping mitochondria in shape [12].
Mitochondrial maintenance and quality control are an concerted eﬀort of protein degra-
dation either through specialized mitochondrial proteases or the UPS, lysosomal degra-
dation triggered through autophagy, and also programmed cell death. The goal of this
study was to further elucidate mitochondrial quality control at the intersection between
ubiquitin-mediated protein degradation and autophagy.
3.1.1.1 Structural properties of mitochondria Structurally, mitochondria are
highly compartmentalized organelles [13]. As shown in Figure 1, mitochondria contain
two lipid bi-layers, an OMM and an IMM, leading to the IMS, topologically equivalent
to the cytoplasm, and the matrix, an internal space that contains enzymes important
for fatty acid oxidation as well as for the Krebs tricaboxylic acid cycle (TCA). The ma-
trix also hosts mitochondrial DNA (mtDNA) and is the site of mitochondrial protein
synthesis[14, 15]. The IMM is highly impermeable, and by folding in a convoluted man-
ner, forms the cristae, a large surface area where the respiratory chain (RC) complexes
IV are located [16]. The IMS is part of the proton gradient necessary for adenosine
triphosphate (ATP) generation across the IMM [17], where an increased concentration
of protons in the IMS compared to the matrix is established during mitochondrial respi-
ration (see 3.1.1.2). The inner boundary membrane as part of the IMM forms a double
membrane layer with the OMM. It houses translocase of the inner membrane (TIM) com-
plex, which facilitates protein transport across the IMM into the matrix [18]. The protein
complexes of the electron transport chain (ETC) are largely localized to the cristal region
of the IMM. The invaginations or cristae of this cristal membrane contain the majority
of the mitochondrial cytochrome c pool [19].
The OMM acts as a diﬀusion barrier [20], while permitting size-restrictive passage across
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Figure 1: Mitochondrial compartments. Shown is a scheme of a mitochondrion with annotations
for the diﬀerent mitochondrial compartments. Mitochondria are double membrane-bound organelles
with an outer and inner mitochondrial membrane (IMM). The mitochondrial matrix is the inner
most part of mitochondria harboring mtDNA and also the enzymatic machinery for the tricarboxylic
acid cycle (TCA cycle). The IMM is highly folded forming so called cristae in order to expand the
membrane surface for the components of the electron transport chains (ETC). The ETC is generating
the mitochondrial membrane potential ultimately used for the production of ATP by complex V.
Ion transporters such a voltage-dependent anion channel (VDAC) are involved in Ca2+ buﬀering.
Cytochrome c is a small protein localized in intermembrane space as part of the ETC.
the membrane through porins and receptor-mediated traﬃc via the translocase of the
outer membrane (TOM) complex [21, 22]. Mitochondria-associated membranes (MAM)
[23] are sites of connection of the OMM to the endoplasmic reticulum (ER) and are in-
volved in both Ca2+ [24] and inﬂammasome signalling [25]. Additionally, the OMM is
lipids source for the formation of the isolation membrane during autophagy [26].
3.1.1.2 Mitochondrial energy production The structure, function, and organi-
zation of the respiratory chain have been under investigation since Otto Warburg dis-
covered Atmungsferment, the enzymatic basis for cellular respiration [27]. Mitochondria
are the site of OXPHOS and generate as much as 90 % of all ATP used by cells via a
chemiosmotic mechanism. Mitochondria generate the energetic potential via the respira-
tory complexes I to IV [28]: complex I (CI or reduced nicotinamide adenine dinucleotide
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(NADH):ubiquinone oxidoreductase), complex II (CII or succinate:ubiquinone oxidore-
ductase), complex III (CIII or ubiquinol:cytochrome-c oxidoreductase), and complex IV
(CIV or cytochrome-c oxidase). Together with complex V (CV or FO F1 -ATP-synthase)
they form what is usually called the OXPHOS system (Figure 2). The entry point for
mitochondrial metabolism consists of electron donors. These donors are generated during
the metabolization of glucose by the TCA and though ß-oxidation of fatty acids. Com-
plex I, Complex III, and Complex IV generate proton motive force across the IMM and
their actions are facilitated by Complex II and electron transfer cofactors (i.e., ubiquinone
and cytochrome-c). Proton translocation back to the mitochondrial matrix drives Com-
plex V, which is coupled to ATP synthesis. Most of the ATP produced by Complex V
is exchanged against cytosolic adenosine diphosphate (ADP) through a speciﬁc adenine
nucleotide carrier to supply the rest of the cell with energy and to maintain the ADP
phosphorylation capacity of mitochondria [29].
3.1.1.3 Mitochondria are highly dynamic organelles Mitochondria are highly
dynamic organelles forming an organellar network shaped by the balanced ﬁssion and
fusion of mitochondrial tubules. The integrity of the mitochondrial network relies on
the ability of individual subunits to establish new connections with or break away from
the network. Fusion of individual mitochondrial subunits with the network allows for
the exchange of mitochondrial DNA, proteins, lipids and metabolites, for example to
alleviate localized imbalances of these components or dilute impaired components across
the mitochondrial network. In this manner, the mitochondrial network can act as a buﬀer
against a build-up of damage in individual subunits. Fission on the other hand allows for
easier transport of mitochondria across the cell. At the same time, subunits irreaparably
damaged for example due to accumulating oxidative stress can be separated from the
network and degraded, without further compromising the integrity of the mitochondrial
network. Both fusion and ﬁssion rely on their own sets of mitochondrial proteins.
Mammalian fusion proteins are mitofusin 1 (Mfn1) and mitofusin 2 (Mfn2) [30] on the
OMM as well as Opa1 [31] on the IMM. Mitofusins are thought to facilitate fusion of
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the OMM by tethering opposing membranes, either through heterodimerization of Mfn1
and Mfn2 [32] or Mfn2 homodimers [33]. Fusion of the IMM is performed by Opa1 [34].
Fission of mammalian mitochondria is driven by dynamin-related protein 1 (Drp1) [35],
mitochondrial ﬁssion factor (Mﬀ) [36], mitochondrial dynamics proteins (MiD) 49 and
51 [37] and mitochondrial ﬁssion 1 protein (ﬁs1) [38]. Mitochondrial ﬁssion relies on an
inhibition of fusion proteins and recruitment of cytosolic Drp1 to the OMM [39] where
it may interact with Fis1 [40], although the importance of ﬁs1 has recently been called
into question and may be cell type speciﬁc [36, 41]. Both Mﬀ as well as MiD49 and
MiD51 on the other hand have been shown as essential for a successful ﬁssion event to
take place [42, 37]. After recruitment of Drp1 to the OMM, Drp1 forms oligomeric rings
encompassing the future ﬁssion site [35]. These rings are able to constrict by hydrolyzing
GTP, which eventually leads to scission of the OMM. The importance for balanced ﬁssion
and fusion of mitochondria is highlighted by the diseases connected to dysregulation of
mitochondrial morphology. Lack of proper mitochondrial fusion due to mutations in
fusion factors Mnf2 and OPA1 cause neurodegenerative diseases Charcot-Marie-Tooth 2A
and autosomal dominant optic atrophy, respectively [43]. Lack of mitochondrial ﬁssion
due to mutations in Drp1 are linked to birth defects [44] and optic nerve degeneration
[45].
3.1.2 Mitochondrial damage
3.1.2.1 Generation of reactive oxygen species Mitochondria and oxidative phos-
phorylation open up a highly eﬃcient source of chemical energy for cells (3.1.1.2). How-
ever, chemical reactions involving singlet oxygen come with the price of generating highly
reactive oxygen derivatives, which if left unchecked, wreak havoc on the cell [46]. The
term reactive oxygen species (ROS) is used to describe a variety of molecules and free rad-
icals derived from molecular oxygen. Molecular oxygen in the ground state is a bi-radical,
containing two unpaired electrons in the outer shell (also known as a triplet state). Since
the two single electrons have the same spin, oxygen can only react with one electron at
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a time and therefore it is not very reactive with the two electrons in a chemical bond.
On the other hand, if one of the two unpaired electrons is excited and changes its spin,
the resulting singlet oxygen becomes a potent oxidant as the two electrons with opposing
spins can quickly react with other pairs of electrons, especially double bonds [47].
ETC-linked ROS production was ﬁrst reported a half century ago. It was observed that
antimycin A-treated, isolated mitochondria are producing hydrogen peroxide [48]. Fur-
ther studies identiﬁed the mitochondrial components responsible for ROS production,
including complex I, complex III, and other mitochondria-localized redox systems.
Complex I is the largest and ﬁrst enzymatic complex of the ETC. It is essential for cel-
lular energy production, providing about 40 % of the proton motive force required for
ATP synthesis. It oxidizes NADH to NAD+ and donates the released electrons to the
electron carrier coenzyme Q10 (CoQ10, also known as ubiquinone), linking this process to
the translocation of four protons from the mitochondrial matrix to the IMS [49]. These
electron transfers generate superoxide (O2-) [50]. Superoxide is normally converted to
H2O2 by manganese superoxide dismutase (MnSOD); the former can easily diﬀuse across
the membranes and be quickly reduced to water by mitochondrial and cytoplasmic per-
oxiredoxins, catalases, and glutathione peroxidases. It is estimated that 40 % of all
mitochondrial disorders are related to mutations of complex I subunits [51]. Parkin-
son's disease (PD) is one of the typical examples. PD is characterized with a progressive
loss of dopaminergic neurons and cell bodies of the substantia nigra pars compacta and
nerve terminals in the striatum (see also 3.3.4). ROS are considered as one of the main
pathogenesis factors based on dopamine oxidation-related metabolic pathways. Under
physiological circumstance, oxidative deamination of dopamine by monoamine oxidase
produces hydrogen peroxide [52]. In the pathological pathway, dopamine can be oxidized
non-enzymatically by superoxide forming dopamine quinone which will be reduced by
mitochondrial complex I to generate semiquinone followed by a transfer of its electron
to molecular oxygen to form superoxide, completing a vicious oxidative cycle [53]. Both
somatic and mitochondria DNA point mutations might cause complex I dysfunction,
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thus subsequently linking ROS-mediated damage to neurodegenerative disorders such as
Leber's hereditary optic neuropathy (LHON), Leigh's syndrome (LS), and mitochondrial
encephalomyopathy, lactic acidosis, and stroke like episodes (MELAS) [54].
Complex II, succinate-ubiquinone oxidoreductase, commonly known as succinate dehy-
drogenase (SDH), is a tetrameric iron-sulfur ﬂavoprotein of the IMM and acts as part
of the TCA and respiratory chain [29]. SDH catalyzes the conversion of succinate to
fumarate, yielding reducing equivalents in the form of reduced ﬂavin adenine nucleotide
(FADH2). This is followed by a reduction of ubiquinone to ubiquinol [55].
Typically, complex II is excluded from the list of potential candidates for important
physiological contributors of ROS [56]. It is partially due to fact that the succinate level
in the tissue is low. During oxidation of succinate in isolated respiring mitochondria,
electron ﬂow can bifurcate forming direct (towards cytochrome oxidase) and reverse (to-
ward NAD; rotenone-blocked) transport with the latter requiring energy input [57, 58].
The succinate-driven ROS generation during reverse electron transport from succinate
to NAD resulting in the formation of NADH is higher when compared with that form-
ing under direct oxidation of NAD-dependent substrates [59]. The observed relationship
between ROS formation and the redox state of the couple NADH/NAD resulted in the
proposition that the ROS formation is directly proportional to the level of reduction of
NAD.
The role of complex II in maintaining and modulating the mitochondrial and cellular
redox environment remains undetermined. It is unknown whether in vivo mitochondria
reverse electron transfer from complex II to complex I occurs, and whether under physio-
logical conditions the reverse electron transport could result in substantial ROS produc-
tion considering that physiological concentrations of NADH would signiﬁcantly attenuate
O2·- production under conditions where reverse electron transport could be observed in in
vitro model systems [60]. Complex III (ubiquinol-cytochrome c oxidoreductase) accepts
reducing equivalents formed in complexes I and II and processes them by the Q-cycle
operating mechanism. Operation of this cycle is initialized by ubiquinol, which releases
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a proton to the IMS and donates one electron to the Riske iron-sulfur protein producing
unstable semiquinone on the outer side of the IMM. The semiquinone serves as an elec-
tron donor for hemes of cytochrome bL, and then of cytochrome bH which is located close
to the inner side of the membrane. Cytochrome bH reduces ubiquinone in an antimycin
A-sensitive way producing ubisemiquinone followed by its further reduction with a second
electron and protonation [61]. However, if the ﬂow of electron through the complex III is
stalled e.g. following application of complex III inhibitors such as antimycin A, myxoth-
iazol, or stigmatellin, semiquinone levels are elevated resulting in more opportunities to
donate single-electron to reduce oxygen [62, 63].
Aside of complex I and III as the major production site of mitochondrial ROS, also com-
plex IV is able to generate ROS [64]. Complex IV, also called cytochrome c oxidase, is a
protein- phospholidpid complex containing four redox centers (CuA, cyt. a, cyt. a3 and
CuB) involved in electron transport and the conversion of oxygen to water. During this
process, several -peroxyl and -ferryl intermediates are produced, which are considered as
potential sources of free radicals [65, 66]. In vitro mitochondrial ischemia/reperfusion
experiments showed signiﬁcant increase of ROS production, and complex IV has been
suggested to contribute around 30-35 % of total mitochondrial superoxide production
[67].
While mitochondria are a major producer of ROS, these organelles are also a major
sink for these toxic metabolites. Only if the antioxidant capacity of mitochondria are
overwhelmed can ROS accumulate and cause signiﬁcant mitochondrial as well as cellular
damage. As result of aging or disease, the eﬃciency of the ETC is diminished causing
increased production of ROS. In case of insuﬃcient antioxidant defense, increased levels
of ROS cause a further decrease of ETC eﬃciency leading in a vicious circle to increased
ROS production. It is widely accepted that oxidative damage is at the bottom of many
age-related disorders and that keeping oxidative damage to mitochondrial components in
check is essential to maintain mitochondrial energy production and, thus, cellular func-
tion.
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Figure 2: The ETC. The ETC is composed of ﬁve complexes (complex I - V). The substrates NADH
and succinate generated by the TCA pass electrons through the ETC (I - IV) to O2 generating H2O,
meanwhile protons (H+) are transferred out of the matrix into the intermembrane space generating an
electro-chemical potential across the IMM to store the energy. At last, H+ ﬂow back through complex
V or F0F1-ATPase into the matrix compartment driving ATP production. As byproduct of OXPHOS,
the ETC is involved in ROS production. ROS are being neutralized by local antioxidants, such as
superoxide dismutase 2 (SOD2). However, overwhelming ROS production due to mitochondrial
dysfunction will lead to oxidative stress. Inside the ETC, complex I and III are the two major sites of
ROS production. For example, ROS production increases after inhibition of complex I by rotenone
or complex III by antimycin.
3.2 Mechanisms of cellular quality control and their connection
to mitochondrial maintenance
A major cause for mitochondrial dysfunction and associated disease is oxidative stress
(3.1.2.1). Several mechanisms are in place to deal with oxidative stress and damaged
mitochondrial components including mtDNA, lipids and proteins. Antioxidant activity is
the ﬁrst line of defense directly detoxifying reactive species to prevent direct damage to
mitochondrial components. However, additional mechanisms are in place trying to repair
damage caused by ROS escaping the antioxidant defense. These mechanisms are active
on the level of the entire cell (3.2.1), the organellar level (3.2.4.2), or the level of damaged
proteins (3.2.3).
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3.2.1 Mitochondria and programmed cell death
Programmed cell death or apoptosis, the last line of defense in mitochondrial quality
control, is a process whereby cells are induced by either intrinsic or extrinsic signals to
die. Dysregulation of this process leads to several diseases ranging from neurodegenerative
disease to cancer and viral infections [68]. A wide variety of neurological disorders such
as Alzheimer's disease (AD) (3.3.3), PD (3.3.4), amyotrophic lateral sclerosis (ALS) and
others are characterized by a loss of neuronal cells. In these diseases, inappropriate
apoptosis results in the untimely death of neurons causing ultimately dysfunction of the
central nervous system [69]. On the other hand, cancer cells are able to survive due
to their decreased ability to undergo apoptosis in response to cytotoxic conditions [70].
Thus, apoptosis is an essential process for the removal of damaged or harmful cells, so
that the organism as a whole can survive [71]. As opposed to death-receptor induced
apoptosis, intrinsic programmed cell death is initiated by the release of apoptotic factors
such as cytochrome c from the mitochondria to the cytosol. The release of these apoptotic
factors requires mitochondrial outer membrane permeabilization (MOMP) modulated by
various pro- and anti-apoptotic proteins [72]. It was found that cytochrome c, a 15kD
redox carrier protein, responsible for the electron transfer between complex III and IV in
the electron respiratory chain, is released during MOMP subsequently leading to caspase
activation [73]. Thus, mitochondria are an important hub for integrating diﬀerent intrinsic
apoptotic signals and are involved in important cellular life-death decisions which upon
dysregulation can lead to the development of cancer or neurodegeneration.
3.2.2 The UPS
The UPS constitutes one of the principal pathways for cellular protein homeostasis. The
UPS plays a key role in regulating many crucial processes including cell cycle progression,
DNA repair, apoptosis and gene transcription by mediating the elimination of relatively
short-lived regulatory proteins when they are no longer needed. In addition to modulat-
ing cellular activities, it also controls the degradation of unfolded or misfolded proteins
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to prevent cellular damage [74].
For substrate recognition, the UPS relies on tagging substrates with the 76 amino acid-
short protein modiﬁer ubiquitin. Upon ubiquitination, substrate proteins are targeted by
the 26S proteasome for degradation into peptide fragments followed by further degrada-
tion into their component amino acids by cytoplasmic peptidases. This process occurs
in the cytoplasm and nucleoplasm of the cell [75]. The 26S proteasome is a multimeric
complex consisting of about 31 diﬀerent proteins. It is comprised of two diﬀerent sub-
complexes, the 19S cap complex and the 20S proteolytic core [76]. The 19S cap is
responsible for regulating access to the 20S core recognizing ubiquitinated substrates,
removing and recycling their ubiquitin chains by complex component deubiquitinating
enzymes [77, 78]. Next, bound proteins are unfolded and fed into the barrel-shaped 20S
proteolytic core for degradation [79]. Once inside the 20S proteolytic core, substrate
proteins are sequentially cleaved into small peptides by three diﬀerent proteolytic activ-
ities [80, 81]. In addition to the 19S cap complex, proteasome activity and function is
regulated through binding with a variety of proteins, such as chaperones or cofactors,
which regulate subcellular localization and substrate speciﬁcity. Sec61 e.g. targets the
26S proteasome to the ER membrane [82, 83].
3.2.2.1 The machinery of ubiquitination
3.2.2.1.1 Ubiquitin activating, ubiquitin conjugating and ubiquitin ligating
enzymes Ubiquitination is a covalent, post-translational protein modiﬁcation where a
small 76 amino acid ubiquitin (Ub) moiety via the C-terminal carboxyl is covalently con-
jugated onto a lysine residue of a target protein (Figure 3). This is accomplished through
the joint action of three families of enzymes [84]. In a ﬁrst step, the E1 ubiquitin-
activating enzyms binds individual ubiquitin molecules in an ATP-dependent manner via
a high-energy thioester linkage between the ubiquitin carboxy terminus and a cysteine
side chain on the E1 enzyme. This activated ubiquitin is subsequently transfered onto
a E2 ubiquitin-conjugating enzyme again in a thioester linkage. An ubiquitin ligase or
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E3 enzyme then binds both the E2-ubiquitin complex and a substrate protein facilitating
ubiqutin transfer [85]. This substrate can either be a target protein or any of the seven
lysine residues of ubiquitin leading to the formation of poly-ubiquitin chains [86]. While
there is only one ubiquitin-activating enzyme, about 50 E2 enzymes and hundreds of E3
enzymes are found in the human genome [87]. This allows for multiple combinations
of E1, E2 and E3 enzymes conferring very selective substrate speciﬁcity for ubiquitina-
tion [88]. Depending on the type of ubiquitin ligase, binding of the E2 complex and the
substrate occur either simultaneously or sequentially [89]. There are two main groups
of E3 ligases classiﬁed according to their catalytic domain. Homologous to the E6AP
C-Terminus (HECT) ubiquitin ligases generate Ub-thiolester-intermediate prior to estab-
lishing an isopeptidic bond between the C-terminus of ubiquitin and an amino group on
the substrate protein, while really interesting new gene (RING)-ﬁnger E3 ligases facilitate
the transfer of activated ubiquitin directly from E2 to the substrate[90] without forming
an E3-ubiquitin intermediate.
Depending on ubiquitin conjugating and ligating enzymes involved, the outcome of ubiq-
uitination can be manifold. Substrate proteins might be mono-ubiquitinated, multiply
mono-ubiquitinated, or poly-ubiquitinated with ubiquitin chains of diﬀerent conﬁgura-
tion with the most common form being lysine 48 linked ubiquitin chains. For ubiquitin-
dependent degradation by the 26S proteasome a minimum of four Lys48 linked ubiquitin
moieties seems to be required [91]. More recently, polyubiquitin chains involving Lys6,
Lys11, Lys27 and Lys29 [92, 93] and heterogeneous chains involving Lys11, Lys48 and
Lys63 linkages [94] have also been implicated in proteasomal targeting [95].
3.2.2.2 Determining the fate of ubiquitinated proteins
3.2.2.2.1 DUBs Next to the complex system of ubiquitinating enzymes, a class of
dDUBs facilitates the removal of ubiquitin chains. These DUBs are able to hydrolyze
all types of polyubiquitin chains [96]. The 19S lid of the 26S proteasome contains DUB
activity [97, 98]. The removal of poly-Ub chains by DUBs associated with the protea-
15
Figure 3: The UPS. Substrate proteins are recognized by E3 ubiquitin ligases and are subsequently
conjugated with ubiquitin chains. These chains serve as recruitment signals for subsequent traﬃcking
to the 26S proteasome for degradation into peptides and component amino acids.
somal lid precedes the threading of unfolded proteins through a narrow pore into the
proteolytic chamber of the core 20S proteasome [99, 100, 101]. The removal of ubiquitin
prior to degradation also recycles this essential modiﬁer and replenishes the cellular pool
of free ubiquitin. It follows that DUB activity can have distinct outcomes for proteaso-
mal turnover of proteins: some DUBs facilitate degradation, whereas others may stabilize
proteins destined for degradation [102].
In addition to their important role in ubiquitin recycling, DUBs also regulate the fate
of subcellular proteins makes them a prominent diagnostic and therapeutic target for
research [103]. Multiple studies have clearly illustrated the auto-ubiquitylation of E3
ligase and their subsequent interaction with DUBs [104]. DUBs have been classiﬁed
into ﬁve families [105]. Papain-like cysteine proteases with the ubiquitin-speciﬁc pro-
teases (USP), the ubiquitin C-terminal hydrolasess (UCHs), the ovarian tumor domain
proteases (OTUs), the Josephin domain proteases, and zinc-dependent metalloproteases
containing a JAB1/MPN/Mov34 (JAMM) [106].
16
The OTU family of DUBs has emerged as regulators of important signaling cas-
cades. A20 [107], OTUD7B/Cezanne [108] and OTULIN [109] regulate NF-κB signaling,
OTUD5/DUBA regulates interferon signaling [110], OTUD2/YOD1 and VCPIP regulate
p97-mediated processes [111], while OTUB1 is involved in the DNA damage response
[112]. The astonishing variety of diﬀerent types of DUBs might be explained by the com-
plexity of ubiquitin modiﬁcation. DUBs must display various layers of speciﬁcity. They
must distinguish not only between ubiquitin and ubiquitin-like modiﬁcations but also
between the eight ubiquitin linkage types. Moreover, chain topology and length may also
aﬀect DUB activity [96]. In sum, DUBs are what phosphatases are to kinases and are an
integral part of the ubiquitination machinery and fulﬁll important regulatory functions.
3.2.2.2.2 P97  a key component of the UPS P97, also called valosin containing
protein (VCP), or CDC48 in yeast is a member of the ATPase associated with diverse
cellular activities (AAA ATPase) family of proteins [113, 114, 115]. P97 is highly con-
served and expressed in mammals, with around 1 % of total cellular protein being P97
[116]. It is involved in a wide variety of regulatory functions, which are conferred through
cofactors, in the cytosol [117], the plasma membrane [118], the nucleus [119], and various
organelles, such as the endoplasmic reticulum, [116], mitochondria [120], golgi [121], lyso-
somes [118], autophagosomes [122] and peroxisomes [123, 124]. These functions of P97
include cell cycle regulation [125], control of membrane fusion [126, 127], DNA damage
response [119], and various aspects of the UPS [128, 129, 115].
Structure of p97
Initially identiﬁed as a homohexameric particle by negative stain electron microscopy,
p97 was shown to possess ATPase activity that is dependent on its oligomeric state and
the presence of Mg2+ [130, 131]. Subsequently, the crystal structure of the N-domain and
ﬁrst ATPase domain (ND1) was solved by crystallography [132, 133, 134]. The hexamer
displays a mushroom-like shape where two rings of ATPase domains stack on top of each
other and the N-domain is co-planar to the D1 ATPase domain in ADP-bound p97 and
in an `up' conformation in the ATP-bound state [135]. The D1 and D2 ATPase domains
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both fold into typical AAA domains with an α/β-subdomain followed by a helical sub-
domain. Of the 12 ATPase domains in a p97 hexamer, the D1 domains are primarily
involved for oligomerization, while the D2 domains play a larger role in ATP hydrolysis
for force generation [136, 137]. There is some evidence that the D1D2 linker is required
for activity. While D1 domain alone displays negligible ATPase activity, a slightly longer
protein containing the 20 aa D1D2 linker possesses ATPase activity roughly half of full-
length p97 [138, 136, 139]. ATP hydrolysis is also regulated by inter-subunit interactions
between the D2 domain and the C-terminal tail of the neighboring protein [140, 141].
P97 processes ubiquitinated client proteins
P97 together with its cofactors recognizes and processes ubiquitinated client proteins
[123]. One of the ubiquitin mediated pathways with a well-established role for p97 is
ER associated degradation (ERAD) [116, 142]. ERAD governs the retrotranslocation
of misfolded and superﬂuous proteins, of both luminal and membrane-bound, from the
ER to the cytosol. First, ERAD consists of a recruitment step from the ER-lumen to
the ER-membrane. This is followed by ubiquitination of the substrate protein in the
ER membrane through specialized, ER-membrane anchored E3 ubiquitin ligases. P97
cofactors on the ER-membrane then recruit P97 [143], which then extracts the misfolded
proteins through ATP hydrolysis from the ER-membrane [144]. After extraction, these
proteins may undergo further processing by cofactors, for example removal of sugars from
glycoproteins [145], ubiquitin chain elongation [146], or ubiquitin removal by DUBs [147].
Ultimately, retrotranslocation ends with degradation of the substrate by the proteasome,
although DUBs can divert certain substrates from proteasomal degradation through deu-
biquitination [122].
P97 can also act as part of a positive feedback loop through recruitment of an E4 ubiqui-
tin chain elongation factor, where oligo-ubiquitinated substrates are poly-ubiquitinated
before proteasomal degradation [148]. Transfer of ubiquitinated substrate proteins to the
proteasome is also regulated. P97 cofactors UFD2 and RAD23 promote the transfer of
ubiquitinated substrates to the proteasome [148], while the cofactor UFD3 acts in an
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antagonistic manner [149]. Similar to its segregase activity, P97 aids in the unfolding
of its substrates, which facilitates processing by the proteasome [150, 151]. The central
role of p97 for the UPS is especially evident after inhibition of P97, which leads to the
accumulation of ubiquitin conjugates in the cytosol [152, 153].
P97 adapter proteins and cofactors
A large collection of p97-interacting proteins has been identiﬁed. These proteins either
function as adaptors that link p97 to a speciﬁc subcellular compartment or substrate, or
serve as cofactors helping to process substrates. Binding of and competition between p97
cofactors regulates p97 activity. Although a few proteins such as PLAA/Ufd3, PNGase,
HOIP, and Ufd2 bind p97 at the short C-terminal tail [149, 154, 155, 98, 156, 157], the
vast majority of p97-interacting proteins bind N-domain [158]. Representative N-domain-
interacting proteins include Ufd1, Npl4, p47, ataxin3, and FAF1. Binding of cofactors
is mediated by a small group of conserved protein-protein interaction motives. Sequence
analyses identiﬁed several frequently occurring p97-interaction patterns such as the UBX
motif [159], the VCP interacting motif (VIM) [160], VCP-binding motif (VBM) [161] and
SHP box [162].
The UBX domain is an 80-residue module structurally homologous to ubiquitin and
found in a several p97 cofactors. The VCP-interacting motif (VIM) is a linear sequence
motif (RX5AAX2R) found in a number of p97 cofactors or adaptors including gp78
[163], SVIP (small VCP-inhibiting protein) [164] and VIMP (VCP-interacting membrane
protein) [165]. The VBM domain features a highly polarizing linear sequence motif
(RRRRXXYY) found in ataxin-3, Ufd2 and Hrd1 [161]. The SHP box is a short amino
acid stretch enriched in hydrophobic residues, which can be found in p47 [166], Ufd1-Npl4
[167] and Derlin-1 [168, 169, 165]. The cofactors can be divided into two groups depend-
ing on what part of p97 they interact with. The larger group of cofactors binds the p97
N-domain, via UBX, UBX-L, VIM, VBM or SHP (binding segment 1) motif [128, 170].
A smaller group binds the very C-terminus of p97, via peptide N-glycosidase/ubiquitin-
associated (PUB) (PNGase/UBA- or UBX-containing proteins) and PUL (PLAA, Ufd3p
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and Lub1p) domains.
3.2.2.2.3 UBX domain containing cofactors UBX-domain containing proteins
represent the largest family of p97 cofactors with 13 members identiﬁed in the human
genome. The UBX domain has a tridimensional structure similar to ubiquitin [171] and
interacts with the p97 N-terminus [159]. UBX proteins can be further classiﬁed into two
main groups based on their domain composition: UBA-UBX and UBX-only proteins.
UBA-UBX proteins (p47, UBXD7, UBXD8, FAF1, and SAKS1) contain an additional
ubiquitin-associated (UBA) domain at their N-terminus, which enables them to bind
ubiquitinated substrates [172]. UBX-only proteins (UBXD1, UBXD2, UBXD3, UBXD4,
UBXD5, ASPL, p37, VCIP135 and YOD1) lack such an UBA domain and therefore likely
ability to bind polyubiquitinated proteins [173].
UBA-UBX proteins bind ubiquitinated substrates in a manner that is enhanced upon
inhibition of the proteasome, suggesting that they function as ubiquitin-receptors in the
ubiquitin-proteasome pathway. Furthermore, they interact with an assortment of HECT
and RING-domain E3 ubiquitin-ligases, including a large number of cullin-ring ligase
subunits [173]. Thus, each UBA-UBX protein is likely to target a particular subset of
substrate proteins carrying an ubiquitin modiﬁcation. UBX-only proteins on the other
side do presumably not interact with ubiquitin and, as a consequence, the type of sub-
strates they target is less clear. The distinctive substrate speciﬁcity of each UBX protein
is the key to deﬁning the p97 functions they mediate [174]. The family of UBX domain
[175, 171] proteins appear to associate with p97 via their UBX domains [176], and UBX
proteins are therefore generally considered to function as p97 adaptors. The approxi-
mately 80 amino acid long UBX domain displays a remarkably similar structure to that
of ubiquitin [171]. A loop region in the p47 UBX domain lacking in ubiquitin, appears to
be speciﬁc for interaction with a hydrophobic binding pocket in the N-terminal part of
p97 [177]. Another group of proteins, containing the so-called PUB [178] or PUG [179]
domain, was also shown to mediate interaction with p97 [180]. UBX and PUB domains do
not bind to p97 in a mutually exclusive manner [180], and accordingly the PUB binding
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site maps downstream of the UBX binding site [157]. The structure of the PNGase PUB
domain was recently solved [180], revealing a hydrophobic groove which binds p97, an
association which is occluded upon tyrosine phosphorylation of p97 [157]. Interestingly,
many of the UBX family of adaptors have no identiﬁed ubiquitin-association domain, and
no other functional domain to suggest a function. The diversity within the UBX family
suggests an array of potential eﬀects on cellular processes and it is of high interest to
determine the function of other known p97 adaptors.
3.2.2.2.4 Non-UBX domain containing cofactors While the UBX domain may
constitute the major p97 interaction domain, the bulk of the functional work deciphering
the speciﬁc roles of p97 cofactors has been done with the non UBX containing inter-
actors. These p97 cofactors can be further divided into two subgroups, adapters and
accessory proteins. Adapters are required for substrate binding, while accessory proteins
may use p97 as a docking site to perform a speciﬁc enzymatic function on the already
associated substrate. The majority of non-UBX p97 interactors have been shown to per-
form a variety of key roles in mediating ERAD. Arguably the two best studied and most
important p97 adapters, Npl4 (nuclear protein localization 4) and Ufd1 (ubiquitin fusion
degradation 1), form a heterodimer crucial for binding p97 in a 1:1 ratio [167]. Npl4-Ufd1
function as essential substrate recruiting factors binding to ubiquitinated substrates at
the ER membrane linking p97's physical conformational change upon ATP hydrolysis to
the translocation of these proteins into the cytosol [145, 152, 181, 182]. p97 interacting
proteins consist not only of adapters, but also accessory proteins that use p97 as a docking
site to target for their speciﬁc functions. They are called substrate-processing cofactors.
They include the deglycosylase, PNGase I, the E3 ubiquitin ligases Hrd1, gp78, and Ufd2,
and the deubiquitinase Ataxin-3. PNGase I contains a PUB domain responsible for main-
taining the interaction with p97's carboxy-terminal tail [157]. The E3 ubiquitin ligases,
Hrd1, gp78 and Ufd2 have all been identiﬁed as being tied to substrate ubiquitination in
ERAD.
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3.2.2.2.5 UBXD1 Human UBXD1 has recently been shown to be an abundant and
stable protein that localizes to the nucleus, cytosol, microsomal pellet, and centrosomes in
HeLa cells [175]. Interestingly, UBXD1 contains from the N- to the C-terminus a valosin-
containing protein (VCP) interacting motif (VIM), a peptide N-glycosidase/ubiquitin-
associated (PUB), as well as an ubiquitin regulatory X (UBX) domain. Unlike other
UBX domain containing proteins which bind to p97 via their UBX domain, UBXD1 in-
teracts with p97 via its VIM and PUB domain [183]. This is due to the absence of a
phenylalanine-proline-arginine conserved motif in between β-strands 3 and 4 within the
p97 interaction site of UBXD1 [175].
Recently, insights into the function of UBXD1 became available. Initial work suggests
that UBXD1 plays a role in ERAD through moderate defects in the clearance of an
ERAD substrate, CFTRΔF508 upon UBXD1 overexpression [184]. In addition, UBXD1
was shown to co-purify with a known member of the ERAD pathway, the E3 ubiquitin
ligase Hrd1 one of two main ubiquitin ligases involved in ubiquitinating ERAD substrates.
The authors theorize that this interaction is likely indirect, instead mediated by p97 [175].
Recent work, however, has provided some convincing evidence that UBXD1 does play an
important role in directing p97's function, not only in ERAD but also in endolysosomal
sorting. UBXD1 and p97, have been implicated to be key mediators in the internal-
ization and post-endocytic traﬃcking to the lysosome of membrane protein Caveolin-1
[185]. Furthermore, UBXD1 is of clinical relevance, as p97 mutations linked to inclusion
body myopathy associated with Paget's disease of the bone and frontotemporal dementia
(IBMPFD) and ALS are defective at interacting with UBXD1 [185].
UBXD1 is of particular interest to study due to the lack of a clear ubiquitin binding do-
main, in addition to the unique diﬀerences within its UBX domain (lack of phenylalanine-
proline-arginine motif essential for p97 interaction). Additionally, it is one of a few adap-
tors that have been shown to bind both at the N-terminal and C-terminal domains of
p97. Work presented here will show pro-mitophagic function for UBXD1, which acts as
a mitochondrial recruitment factor for p97 during Parkin-dependent autophagic removal
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of damaged mitochondria.
3.2.2.2.6 YOD1  a DUB linked to UBXD1 and p97 YOD1/OtuD2/DUBA8
is a ubiquitin-speciﬁc protease containing a UBX domain, considered a hallmark of p97-
associated proteins [159]. YOD1 is the closest homolog of S. cerevisiae Otu1, which
associates with Cdc48 to regulate the processing of the ER-membrane embedded tran-
scription factor Spt23, a crucial component of the OLE pathway [98]. Although highly
conserved, the function of YOD1 is not clear in higher eukaryotes. The human genome
lacks a homolog of Spt23, suggesting that YOD1 participates in other, presumably con-
served, cellular processes. YOD1 comprises three domains, an N-terminal UBX domain, a
central otubain domain, and a C-terminal C2H2-type zinc ﬁnger domain [111]. Recently,
YOD1 was suggested to act together with UBXD1 and p97 in the autophagic removal of
ruptured lysosomes by selectively removing K48-linked ubiquitin chains from lysosomes
thereby improving recognition by the autophagic machinery [186].
3.2.3 UPS-mediated protein degradation on mitochondria
3.2.3.1 Outer mitochondrial membrane associated degradation Recognition
and elimination of misfolded proteins are essential cellular processes. More than thirty
percent of the cellular proteins are targeted to the secretory pathway. They fold in the
lumen or membrane of the endoplasmic reticulum from where they are sorted to their
ﬁnal destination. The folding process, as well as any refolding after cell stress, depends
on chaperone activity. In case, proteins are unable to acquire their native conformation,
chaperones with diﬀerent substrate speciﬁcity and activity guide them to elimination.
For most misfolded proteins of the ER this requires retrotranslocation to the cytosol and
polyubiquitylation of the misfolded protein through (ERAD). Thereafter ubiquitinated
proteins are guided to the proteasome for degradation [187]. Similar to the ER, mito-
chondria were recently linked to UPS in form of outer mitochondrial membrane associated
degradation (OMMAD) [188] (Figure 4). Interestingly proteasome inhibitors can increase
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Figure 4: Outer mitochondrial membrane associated degradation or OMMAD refers to the protein
quality control machinery localized on the outer mitochondrial membrane, in which multiple ubiquitin
ligases namely MARCH5, IBRDC2, RNF185, MULAN/MAPL and Parkin are involved. OMMAD is
not only restricted to protein quality control. Other mitochondrial functions such as morphology and
mitophagy are inﬂuenced by OMMAD.
the levels of ubiquitinated mitochondrial proteins, indicating the role that proteasomes
play for mitochondrial protein degradation. In this way, OMM proteins such as Mfn1,
Mfn2 and Mcl-1 were found to be polyubiquitinated and degraded by the proteasome.
Also, several speciﬁc E3 ligases were found to localize to the OMM and were shown to
be involved in the ubiquitylation of mitochondrial proteins, including MULAN, Parkin,
MARCH5, RNF185, and IBRDC2 [189, 190, 191] (Table 1). Among many others, RING-
E3 ligases Parkin, MULAN and MARCH5 are widely studied together with their potential
mitochondrial substrates (mitofusins, Drp1, Mutated SOD1, ETC) (1). Interestingly and
analogous to ERAD, p97 is also involved in promoting extraction of polyubiquitinated
proteins from the mitochondrial membrane and transport to the cytosolic proteasome
[192]. Described by many studies, several mitochondrial dynamics regulators as mito-
fusins and Drp1 are the target of ubiquitination [193]. Thus, by aﬀecting mitochondrial
ﬁssion and fusion machinery, the UPS is certainly connected to mitochondrial dynam-
ics, therefore participating in mitochondrial maintenance. The UPS is also through the
ubiquitin E3 ligase Parkin, which serves to initiate mitophagy (3.2.4.2), connected to
autophagic mitochondrial quality control [194].
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Ubiquitin ligase Localization Mitochondrial Substrates
Parkin cytosol, mitochondria Mcl-1, Mfn1/2, Drp1
Mulan/MAPL mitochondria Omi/HtrA2, Drp1
MARCH5 mitochondria Drp1, Mfn1/2, MuSOD1, ataxin-
3, polyQ
IBRDC2 cytosol, mitochondria Bax
Table 1: Overview of mitochondrial ubiquitin ligases, their localization and known and
potential substrates. Please note Mulan/MAPL is described as ubiquitin as well as SUMO
ligating enzyme.
3.2.4 Autophagy
3.2.4.1 General autophagy Autophagy is a major pathway for endo-lysosomal
degradation of cellular cargo sequestered within double-membrane organelles called au-
tophagosomes. Upon induction of autophagy, autophagosomes form de novo and initially
appear as small membrane structures referred to as isolation membranes or phagophores.
The isolation membranes expand, gradually enclosing a part of the cytoplasm, and even-
tually close to give rise to autophagosomes. Subsequently, the outer membrane of the
autophagosome fuses with the lysosomal membrane, and autophagosome inner mem-
brane and autophagosome cargo are degraded by lysosomal hydrolases. When induced
by starvation, autophagy is largely nonselective with regard to the cargo enclosed in au-
tophagosomes and serves mainly to replenish intracellular metabolite stores. In addition
to unspeciﬁc autophagy, targeted autophagic processes are known. Damaged or superﬂu-
ous organelles such as lysosomes, peroxisomes or mitochondria are degraded in a targeted
fashion through lysophagy [195], pexophagy [196] or mitophagy [197].
The formation of autophagosomes is generally thought to require the action of conserved
machinery that includes the ULK1/Atg1 complex, the class III phosphatidylinositol 3-
kinase complex 1, ATG9, WD-repeat protein interacting with phosphoinositides (WIPI),
and the ATG12 and LC3/GABARAP conjugation systems. All of these components lo-
calize to the isolation membrane at some stage of autophagosome formation. In addition
to these conserved core components, other factors such as cargo receptors are required
for selective autophagy [197]. Autophagy represents a highly conserved process for the
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lysosomal degradation of cytoplasmatic long-lived proteins and organelles. It can result
in ﬁnal decomposition of proteins contributing to a certain form of programmed cell death
(autophagic cell death), but it may also serve as a survival mechanism through intracel-
lular clearance of toxic or damaged proteins and organelles or, in times of starvation,
through protein recycling and maintenance of intermediary metabolism [198].
3.2.4.2 Mitochondria-selective autophagy Mitochondria-selective autophagy or
mitophagy is a specialized form of autophagy for to the elimination of dysfunctional
mitochondria, and is a crucial quality control mechanism to ensure mitochondrial net-
work's integrity and functionality. Besides the removal of dysfunctional mitochondria,
mitophagy is also responsible for mitochondrial degradation during erythrocyte matura-
tion, and it contributes to maternal inheritance of mitochondrial DNA, by eliminating
the sperm-derived mitochondria [199]. In mammals, two major mitophagic pathways
can be distinguished - Parkin-dependent as well as Parkin-independent mitophagy. In
Parkin-dependent mitophagy, damaged or dysfunctional mitochondria are removed by the
concerted action of the PTEN induced putative kinase 1 (PINK1) and of the E3 ubiquitin
ligase Parkin (see also 3.3.4). PINK1 and Parkin accumulate on damaged mitochondria,
ﬂagging these organelles with Parkin-dependent ubiquitination of outer membrane pro-
teins, thus allowing their autophagic degradation [200]. In the PINK1/Parkin indepen-
dent pathway, diﬀerent protein regulators, such as BNIP3L [201], FUNDC1 [202], or
Autophagy And Beclin 1 Regulator 1 (AMBRA1) [203] contribute to the ﬂagging and
recognition of mitochondria. Eﬃcient mitophagy relies on the engulfment of the dam-
aged organelles by a forming autophagosome, without aﬀecting the entire mitochondrial
network. For this reason, mitochondrial network fragmentation is observed prior to mi-
tophagy, which thus results to be strictly connected with mitochondria dynamics and
the machineries controlling the balance between fusion and ﬁssion of the organelles. In
fact, not only the main pro-ﬁssion protein Drp1 is modulated through post-translational
modiﬁcations such as SUMOylation, but also proteins favoring the fusion and transport
of the organelles such as Mfn2 or Miro, are selectively degraded in order to promote
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mitophagy [204]. Interestingly, proteomic studies have shown proteins on the IMM to
be eliminated at rates similar to the turnover of whole mitochondria through mitophagy
[205]. At the same time, proteins of the OMM and mitochondrial matrix redistribute
much faster through ﬁssion and fusion events through the mitochondrial network than
proteins of the IMM [206]. These observations suggest that protein degradation on the
IMM may mainly be a product of mitophagy.
3.3 Mitochondria and neurodegeneration
Mitochondria have a fundamental role in eukaryotic metabolic processes by generating
ATP to maintain cellular functions. Dysfunctional mitochondria deprive cells of energy,
produce cytotoxic ROS, and release proapoptotic mediators to initiate cell death. The
mitochondrial quality-control pathways that evolved to maintain the integrity of mito-
chondria therefore have key roles in the normal function of cells [2, 207]. Many neurode-
generative disorders are age related, which is also the most important risk factors for such
diseases like AD, PD, and ALS. And interestingly, mitochondrial function declines with
aging. It is assumed that mitochondria accumulate mtDNA mutations and, thus, non-
functional proteins during the lifespan of the organism, thus contributing to the process
of aging as well as neurodegeneration due to insuﬃcient ATP production. In addition,
mitochondria are the trigger of intracellular apoptosis responsible for the ﬁnal loss of
neuron cell numbers [208]. Also, extensive literature point at oxidative stress as the key
perpetrator for neurodegeneration further linking mitochondria to the demise of neurons
as the main source of ROS [209]. As oxidative stress causes mitochondrial dysfunction
and as failing mitochondria producing even more ROS [210], a vicious cycle progresses in
which more oxidative stress induces more structural and metabolic damages - nucleic acid
breakdown, enzymatic proteins inactivation, lipid peroxidation - resulting in even more
severe mitochondrial dysfunctions [211]. Thus, mitochondrial dysfunction is the center of
many neurodegenerative disorders. Not only deﬁciencies in mitochondrial respiration are
responsible for neuron loss and cell death, mitochondrial quality control, mitochondrial
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dynamic and apoptosis all play important roles in the survival of neurons.
3.3.1 Dysfunction of p97 and neurodegeneration
Given the crucial role of p97 in maintaining cellular proteostasis, it is not surprising that
autosomal dominant mutations in VCP, the gene encoding p97, lead to a rare multi-
system degenerative disorder IBMPFD, also called VCP disease. IBMPFD is associated
with progressive muscle weakness including heart and respiratory muscles leading to dif-
ﬁculty breathing and heart failure. IBMPFD also aﬀects the bones causing chronic pain
and might lead to frontotemporal dementia. Interestingly, pathogenic mutations in the
N-terminal half of p97 in the interface region between N- and D1-domain suggest that
communication between these two regions is important for disease pathogenesis. Disease-
associated mutations do not appear to alter p97 oligomerization but have been reported
to enhance basal ATP hydrolysis, which is mediated through the D2 domain [212]. How-
ever, this seems not to be an essential requirement for disease pathogenesis as not all
mutations aﬀect ATP hydrolysis [213]. Other studies have found that disease-associated
mutations might aﬀect the association of p97 with certain cofactors [214]. This suggests
that disease-associated mutations in p97 do not lead to a global loss of function but,
instead, to impairment of a distinct subset of p97 functions.
Pathogenic p97 mutations have been suggested to interfere with the interaction be-
tween p97 and UBXD1 aﬀecting ubiquitin-dependent membrane sorting at endosomes
and degradation in lysosomes and implying this pathway in IBMPFD. This altered p97-
UBXD1 interaction seems to weaken substrate recognition. In particular, the interaction
of p97-UBXD1 with caveolin-1 (CAV1), a main component of caveolae, is aﬀected [185].
For degradation, CAV1 is modiﬁed with mono-ubiquitin, a signal important for endosomal
sorting, and transported to intraluminal vesicles in endolysosomes. UBXD1 is necessary
for the endolysosomal traﬃcking of ubiquitinated CAV1 [215]. Mice and patients with
pathogenic p97 mutations accumulate CAV1-positive endolysosomes and have reduced
levels of CAV3, a muscle-speciﬁc caveolin, at the sarcolemmal membrane of skeletal mus-
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cle [215, 215]. Intriguingly, autosomal dominant inherited mutations in CAV3 cause limb
girdle muscular dystrophy 1C, which has phenotypic similarities to p97-associated mus-
cle disease and also shows reduced localization of CAV3 to the sarcolemma [216]. These
data suggest that p97 might have tissue-speciﬁc functions and that the selective dis-
ruption of these cellular processes (e.g. CAV1 or CAV3 sorting) leads to tissue-speciﬁc
phenotypes. Endolysosomal degradation is likely to be more broadly aﬀected in VCP
disease pathogenesis as cells that express mutant p97 have enlarged late endosomes with
absent intraluminal vesicles (ILVs), implicating a defect in multivesicular body (MVB)
biogenesis [215].
3.3.2 Huntington's disease
Huntington's disease (HD) is an inherited neurodegenerative disorder characterized by
unsteady gait and uncoordinated body movements as well as dementia in late stage dis-
ease. Early onset HD as symptomatic overlap to PD. HD is caused by mutations in
Huntingtin causing expansion of CAG triplet repeats. Interestingly, diminished removal
of dysfunctional mitochondria observed in HD suggested impairment in the mitophagy
process. It has been proposed that mutant Huntingtin could impair the delivery of ﬂagged
dysfunctional mitochondria to onforming autophagosomes, because of its reduced inter-
action with the autophagy receptor SQSTM1/p62 [217], and by aﬀecting autophagosome
transport towards the lysosome [218]. Recently, it has been observed that Huntingtin is
involved in selective autophagy, by serving as a scaﬀold for both SQSTM1/p62 and the
autophagy initiation kinase ULK1 [219], re-opening the question about the role of mutant
Huntingtin in these processes. A partial answer has been suggested by the observation
that a reduced delivery of dysfunctional mitochondria to the autophagosome could be
partially rescued when PINK1 is overexpressed, in ﬂy and mice HD models [220]. In ad-
dition, the analysis of PINK1-/- mice indicates that mitophagy levels are very diﬀerent in
various areas of the brain [221], thus suggesting that diﬀerent neuronal population could
rely on or modulate diﬀerent forms of Parkin-dependent/Parkin-independent mitophagy,
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probably in response to diﬀerent stimuli. Thus, recent insight into HD further support
the importance of selective mitophagy and mitochondrial quality control to prevent neu-
rodegeneration.
3.3.3 Alzheimer's disease
Mitochondrial dysfunction in AD is due to the accumulation of Aβpeptides on these
organelles. In particular, Aβtoxicity could depend upon: i) its interaction with mito-
chondrial matrix proteins [222]; ii) the perturbation of the ﬁssion and fusion processes
[223]; iii) the alteration of mitochondrial motility [224]; iv) the disruption of the function-
ality of the electron transfer chain and of the ATP/ADP exchange [223]. Accumulation of
autophagic vacuoles in AD brains suggested defective autophagy as one of the pathogenic
features of AD [225]. Very recently, it has been reported that although the autophagic
machinery is competent in AD neurons, the ﬂux is impaired in the ﬁnal stages of the
process, namely the fusion of autophagosomes with lysosomes [226]. In addition, it has
been reported that Parkin overexpression in an AD mouse model results in an enhance-
ment of the autophagic clearance of defective mitochondria, and in the prevention of
mitochondrial dysfunction [227]. Taken together these observations suggest that whereas
enhanced mitophagy increases the autophagic ﬂux, defective lysosomal removal of au-
tophagic vesicles is responsible for the aberrant accumulation of defective mitochondria
in AD. Further, it has been very recently reported that N-terminal truncated Tau is able
to induce aberrant Parkin recruitment, thus leading to excessive mitophagy, contributing
to synaptic failure [228].
3.3.4 Parkinson's disease
PD is a neurodegenerative disorder causing characteristic movement abnormalities known
as parkinsonism. The disease mainly aﬀects the dopamin-producing neurons substantia
nigra in the midbrain. Death of these neurons and the resulting lack of dopamin is re-
sponsible for the movement disorder and other symptoms such as sleep and emotional
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problems. Most cases of PD are idiopathic and late onset. Rare, early onset PD is caused
by autosomal recessive mutations in the PARK2 gene, coding for the Parkin protein
[229], or by mutations in the PARK6 gene encoding the PINK1 protein [230]. PINK1
and Parkin are key factors acting on the same biological pathway, leading to the tag-
ging and engulfment of dysfunctional mitochondria by the autophagy machinery [231].
PINK1 is a mitochondrial resident protein kinase, which is rapidly degraded after its
import into healthy organelles, by the action of mitochondrial matrix protease (MMP)
and the presenilins-associated rhomboid-like protein (PARL) [232]. Whereas, in dys-
functional mitochondria, characterized by a lack of mitochondrial membrane potential,
PINK1 is not degraded and accumulates on the OMM [233]. OMM-localised PINK1
in turn phosphorylates cytosolic Parkin, as well as mitochondrial ubiquitin chains, thus
providing signals for Parkin recruitment to the damaged organelle [234]. Indeed, Parkin
mediates the ubiquitination of the OMM proteins, including Mfn1 and Mfn2, Miro, the
translocase of outer mitochondrial membrane 20 (TOMM20), and VDAC. Ubiquitinated
Mfn1 and Mfn2 are delivered to the proteasome for degradation, thus stimulating mito-
chondrial ﬁssion and mitochondrial network fragmentation [235]. Other ubiquitinated
proteins are recognised by autophagy receptors, such as p62 and optineurin [236], al-
lowing the selective engulfment of mitochondrial subunits in the forming autophagosome
[237]. The mitophagy process acting through PINK1-Parkin seems to be important not
only to protect neurons from the damage caused by dysfunctional mitochondria in the
soma, but it has been proposed that this system could be very eﬃcient in the removal
of damaged organelles in axons of these cells [238]. Perturbation of the system in PD
patients, could depend upon both mutations in the genes encoding key proteins in the
system [239], but also on altered Parkin solubility, as a consequence of age or oxidative
and/or nitrosative stress [240]. In addition, a number of diﬀerent proteins have been iden-
tiﬁed as important for interacting with and/or being able to modify the PINK1-Parkin
pathway [231]. Notably, among these are proteins able to antagonise Parkin activity, such
as the anti-apoptotic members of the Bcl-2 family Bcl-X or Mcl-1, or DUBs USP30 [241]
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and USP15 [242]. On the other side, Parkin activity is induced by the deubiquitinase
USP8 [243], and mitophagy is induced by its interaction with AMBRA1 [244], whose
localization on the OMM induces mitophagy even in the absence of Parkin [203]. The
relevance of Parkin-independent mitophagy activation has yet to be addressed in PD, as
other ubiquitin ligases have been identiﬁed as able to mark mitochondria for removal. In
fact, it has been proposed that PINK1-generated phospho-ubiquitin on mitochondria is
the main signal for mitophagy and that Parkin acts as an ampliﬁer in the system [245].
Parkin-mediated mitophagy is likely a rare event in vivo and acts only on severely dam-
aged mitochondria only present when other mitochondrial quality control mechanism are
insuﬃcient or overwhelmed [246]. The importance of Parkin-mediated mitophagy to id-
iopathic PD is still not completely understood and other regulators of mitophagy might
be involved in the onset and progression of neurodegenerative diseases [247]. However,
the importance of mitochondrial quality control on all levels for neuronal survival and
prevention of neurodegeneration is strongly supported by the elucidation of mechanism
leading to PD.
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4 Material and Methods
4.1 Materials
4.1.1 Equipment
Equipment Manufacturer
CyAn ADP Analyzer Beckman Coulter (Nyon, CH)
Easyject Plus Electroporator Equibio Ltd (Belgium)
Odyssey CLx Imaging System Li-Cor (DMP AG, Fehraltorf, CH)
Thermomixer comfort VWR (Eppendorf, Basel, CH)
TProfessional TRIO Thermocycler Analytik Jena (Reinach, CH)
Trans-Blot SD Semi-Dry Transfer Cell Bio-Rad (Cressier, CH)
Nanodrop Thermo Scientiﬁc (Waltham, USA)
Scale PM1200 Mettler Toledo (Zurich, CH)
Sterile ﬁlter 0.2 µM Roth (Karlsruhe, D)
Thermomixer Eppendorf (Hamburg, D)
Transfer-blot Semi-Dry Transfer cell Biorad (Berkley, USA)
VisiScope Visitron Systems (Puchheim, D)
Water bath Memmert (Buchenbach, D)
Water puriﬁcation system Millipore (Billercia, USA)
Table 2: Equipment used during this study.
4.1.2 Reagents
Item Order number Supplier
1 Kb plus DNA ladder 10787018 TFS (Reinach, CH)
1,4-Dithiothreitol 6908 Carl Roth (Arlesheim, CH)
Acetic acid (glacial) 100 % 1000631000 Merck Millipore (Zug, CH)
Aceton 650501 Sigma-Aldrich (Buchs, CH)
Adenine A3159 Sigma-Aldrich (Buchs, CH)
Agarose 2267.4 Carl Roth (Arlesheim, CH)
Amersham Protran 0.45 NC 10600002 GE Healthcare (Glattbrugg, CH)
Ammoniumperoxidsulfate 9592.3 Carl Roth (Arlesheim, CH)
Ampicillin sodium salt K029.1 Carl Roth (Arlesheim, CH)
Aureobasidin A 630466 Sigma-Aldrich (Buchs, CH)
BCA protein assay kit 23225 TFS (Reinach, CH)
Bovine serum albumin Fraction V 8076.4 Carl Roth (Arlesheim, CH)
Bromophenol blue 1610404 Bio-Rad (Cressier, CH)
Calcium chloride dihydrate C7902 Sigma-Aldrich (Buchs, CH)
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CCCP C2759 Sigma-Aldrich (Buchs, CH)
D-(-)-Mannitol 4175.1 Carl Roth (Arlesheim, CH)
D-(+)-Glucose G7528 Sigma-Aldrich (Buchs, CH)
D-(+)-Saccharose 6421.1 Carl Roth (Arlesheim, CH)
dam-/dcm- E. coli C2925l NEB (Bioconcept, CH)
DAPI 6335.1 Carl Roth (Arlesheim, CH)
Digitonin HN76.3 Carl Roth (Arlesheim, CH)
Dimethyl sulfoxide D8418 Sigma-Aldrich (Buchs, CH)
DMEM D5671 Sigma-Aldrich (Buchs, CH)
ECL Plus Substrate 32132 TFS (Reinach, CH)
EDTA CN06.1 Carl Roth (Arlesheim, CH)
Ethidium bromide 1410433 Bio-Rad (Cressier, CH)
FBS F7524 Sigma-Aldrich (Buchs, CH)
Fugene 6 E2691 Promega (Dübendorf, CH)
Medical X-ray Super RX-N 47410 19284 FujiFilm (Lucerna-Chem, CH)
Gel Cassettes NC2015 TFS (Reinach, CH)
GenElute kit G1N70-1KT Sigma-Aldrich (Buchs, CH)
Gene Pulser Cuvettes 165-2086 Bio-Rad (Cressier, CH)
Glycerol 3783.1 Carl Roth (Arlesheim, CH)
Glycine 3790.3 Carl Roth (Arlesheim, CH)
HeLa cell line LGC Standards (Wesel, D)
Hepes H3375 Sigma-Aldrich (Buchs, CH)
Histidine Sigma-Aldrich (Buchs, CH)
Hydrochloric acid 9277.1 Carl Roth (Arlesheim, CH)
Hypodermic Needles 25G NN-2516R Terumo (Spreitenbach, D)
Kanamycin sulfate T832.2 Carl Roth (Arlesheim, CH)
Leucine L8912 Sigma-Aldrich (Buchs, CH)
L-glutamine G7513 Sigma-Aldrich (Buchs, CH)
LB broth X968.3 Carl Roth (Arlesheim, CH)
Leupeptin L2884 Sigma-Aldrich (Buchs, CH)
Magnesium sulfate M7506 Sigma-Aldrich (Buchs, CH)
Manganese(II) chloride T881.1 Carl Roth (Arlesheim, CH)
Matchmaker Gold Y2H System 630489 Clontech Laboratories
Methanol 4627.5 Carl Roth (Arlesheim, CH)
MF-Millipore Membrane Filter VMWP02500 Merck Millipore (Zug, CH)
Mounting medium H1000 Vector Labs (ReactoLab, CH)
MOPS M1254 Sigma-Aldrich (Buchs, CH)
NEB 5-α E. coli C2987I NEB (Bioconcept, CH)
NSC-687852 ab142195 Abcam (Lucerna-Chem, CH)
TEMED 2367.2 Carl Roth (Arlesheim, CH)
N-Ethylmaleimide E1271 Sigma-Aldrich (Buchs, CH)
NucleoSpin Gel/PCR Clean-Up 740609.250 Macherey-Nagel (Oensingen, CH)
NucleoSpin Plasmid 470588.250 Macherey-Nagel (Oensingen, CH)
Opti-MEM 11058021 TFS (Reinach, CH)
Orange G O3756 Sigma-Aldrich (Buchs, CH)
Paraformaldehyde 28906 TFS (Reinach, CH)
PBS, 1x D8537 Sigma-Aldrich (Buchs, CH)
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PBS, 10x 70011036 TFS (Reinach, CH
Pepstatin A P5318 Sigma-Aldrich (Buchs, CH)
Peptone 2366.2 Carl Roth (Arlesheim, CH)
Phenylmethanesulfonyl ﬂuoride 78830 Sigma-Aldrich (Buchs, CH)
PEI MAX 40000 24765 Polysciences (Warrington, USA)
Potassium chloride (KCl) P9311 Sigma-Aldrich (Buchs, CH)
Protease inhibitor cocktail 05892791001 Roche, CH
ProtA/G beads E2512 Santa Cruz (Heidelberg, D)
RIPA buﬀer 89901 TFS (Reinach, CH)
Rotiphorese Gel 30 (Acrylamide) 3029.1 Carl Roth (Arlesheim, CH)
Rubidium chloride 4471.1 Carl Roth (Arlesheim, CH)
Superfrost microscope slides 10143560W90 TFS (Reinach, CH)
Sodium dodecyl sulfate (SDS) 2326.2 Carl Roth (Arlesheim, CH)
Sodium Chloride (NaCl) 3957.1 Carl Roth (Arlesheim, CH)
Sodium pyruvate S8636 Sigma-Aldrich (Buchs, CH)
TopBlock TB232010 LuBioScience (Luzern, CH)
Tris base 4855.2 Carl Roth (Arlesheim, CH)
Triton X 100 6683.1 Carl Roth (Arlesheim, CH)
Trypsin-EDTA T3924 Sigma-Aldrich (Buchs, CH)
Tryptophan T0254 Sigma-Aldrich (Buchs, CH)
TWEEN 20 P9416 Sigma-Aldrich (Buchs, CH)
Whatman GB003 WHA10427826 Sigma-Aldrich (Buchs, CH)
Whatman GB005 WHA10426994 Sigma-Aldrich (Buchs, CH)
Yeast extract 2904.1 Carl Roth (Arlesheim, CH)
X-αGal 630462 Sigma-Aldrich (Buchs, CH)
Table 3: Material used during thesis. Supplier TFS - Thermo Fisher Scientiﬁc, NEB-
New England Biolabs.
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4.1.2.1 Antibodies
Antibody order no. supplier usage
mouse anti-cytochrome c 556432 BD (Allschwil, CH) 1:1000 IF
mouse anti-GAPDH sc-32233 Santa Cruz (Heidelberg, D) 1:6000 WB
rabbit anti-GFP G1544 Sigma-Aldrich (Buchs, CH) 1:4000 WB
rabbit anti-GFP ab290 Abcam (Lucerna-Chem, CH) 1:500 IF
mouse anti-p97 MA3-004 TFS (Reinach, CH) 1:1000 IF
rabbit anti-Flag PA1-984B TFS (Reinach, CH) 1:1000 IF,WB
rabbit anti-UBXD1 ab80659 Abcam (Lucerna-Chem, CH) 1:1000 WB
mouse anti-Flag F1804 Sigma-Aldrich (Buchs, CH) 1:1000 IF
mouse anti-myc M5546 Sigma-Aldrich (Buchs, CH) 1:1000 IF
goat anti-mouse-Alexa546 11003 TFS (Reinach, CH) 1:1000
goat anti-rabbit-Alexa546 11010 TFS (Reinach, CH) 1:500
goat anti-mouse-Alexa680 11010 TFS (Reinach, CH) 1:500
goat anti-Rabbit-HRP - TFS (Reinach, CH) 1:20000
goat anti-Mouse-HRP - TFS (Reinach, CH) 1:20000
Table 4: Antibodies used during this work. Antibodies were used for immunoﬂuorescence
(IF) and Western blotting (WB). Supplier TFS - Thermo Fisher Scientiﬁc
4.1.2.2 Composition of buﬀers and media
4.1.2.2.1 2YT medium
NaCl 10 g/l
yeast extract 10 g/l
peptone 12 g/l
MgSO4 20 mM
KCl 10 mM
MgSO4 and KCl were added from sterile 1 M stock solutions after autoclaving.
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4.1.2.2.2 6x Orange G DNA loading dye
Tris/HCl, pH 7.5 10 mM Tris/HCl
Orange G 0.15 % (w/v)
glycerol 60 % (v/v)
4.1.2.2.3 10x Laemmli running buﬀer (SDS-PAGE)
Tris base 30 g/l
glycine 144 g/l
SDS 10 g/l
4.1.2.2.4 2x Laemmli sample buﬀer
Tris/HCl, pH 6.8 125 mM
SDS 4 % (w/v)
glycerol 20 % (v/v)
Bromophenol blue 0.04 % (w/v)
dithiothreitol 100 mM (fresh before use)
37
4.1.2.2.5 PBS-T
10x PBS 10 %
Tween20 0.1 %
4.1.2.2.6 SOB media
peptone 2 % (w/v)
yeast extract 0.5 % (w/v)
NaCl 10 mM
KCl 2.5 mM
MgCl2 10 mM
MgSO4 10 mM
4.1.2.2.7 10x TAE buﬀer
Tris base 400 mM
acetic acid (glacial) 200 mM
EDTA 10 mM
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4.1.2.2.8 Transformation buﬀer 1 (TFB 1)
MnCl2 30 mM
RbCl 100 mM
CaCl2 10 mM
glycerol 15 % (v/v)
pH 5.8
4.1.2.2.9 Transformation buﬀer 2 (TFB 2)
MOPS 10 mM
RbCl 10 mM
CaCl2 75 mM
glycerol 15 % (v/v)
pH 6.8
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4.1.2.3 Enzymes and nucleic acids
Name order number vendor
BamHI R0136 NEB (Bioconcept, CH)
EcoRI R0101 NEB (Bioconcept, CH)
EcoRV R0195 NEB (Bioconcept, CH)
HindIII R0104 NEB (Bioconcept, CH)
NdeI R0111 NEB (Bioconcept, CH)
NheI R0131 NEB (Bioconcept, CH)
NotI R0189 NEB (Bioconcept, CH)
XhoI R0146 NEB (Bioconcept, CH)
Phusion Polymerase M0530 NEB (Bioconcept, CH)
T4 DNA ligase M0202 NEB (Bioconcept, CH)
Shrimp alkaline phosphatase M0371 NEB (Bioconcept, CH)
Table 5: DNA modifying enyzmes used during this study. Supplier NEB - New England
Biolabs.
4.1.2.4 Oligonucleotides
Name Sequence
OAN2020 TCATCTCTCGAGCTATGAAGAAATTCTTTCAGGAGTTCAAG
OAN2021 TGTACTAAGCTTTCACAAGAGCTTCTCGATGGCT
OAN2022 TCATCTGAATTCATGGATTACAAGGATGACGACGA
OAN2024 TCTATCCTCGAGTCACCGCTTGATCTCCTCTGCTGT
OAN2025 TGTACTGGATCCTGAGCCACCTGAGCCACCGTTGAACGTGTAGATCTTCA
TGAT
OAN2333 GTCCGGACTCAGATCTCGAG
OAN2334 AGATGAGAATTCTCAATTGTTTTTTCTCAGCTGAATAATTTTGATAAAGG
CGCCCAGGGAGAACACGCCAATAGCCAGCATGGCGAGAATCAGCAAGAGC
TTCTCGATGGCTG
OAN2398 AGATGACATATGAAGAAATTCTTTCAGGAGTTCAAGG
OAN2399 TCATCTGGATCCTCACAAGAGCTTCTCGATGGC
OAN2400 AGATGACATATGAAGAAATTCTTTCAGGAGTTCAAGGC
OAN2401 TCATCTGCGGCCGCTCACAAGAGCTTCTCGATGGC
OAN2402 TCATCTGGATCCTCACCGCTTGATCTCCTCTG
OAN2403 AGATGACATATGTCGCAGGACACCATCCG
OAN2404 AGATGACATATGCGGGAGCAGAGGCTCAGG
OAN2412 GCTCGTAAGCTTATGGATTACAAGGATGACGACGATAAGTCGCAGGACAC
CATCCG
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OAN2413 GCTCGTAAGCTTATGGATTACAAGGATGACGACGATAAGCGGGAGCAGAG
GCTCAGG
OAN2414 TCATCTGATATCTCACAAGAGCTTCTCGATGGC
OAN2415 AGATGAGCTAGCATGTCCGTCCTG
OAN2416 AGATGAAAGCTTTCAGATCTTCTTCAGAGATGAGTTTCTGCTCAGGGCCG
GGATTCTCCTCCACGTCACCGCATGTTAGAAGACTTCCTCTGCCCTCCTT
GTACAGCTCGTCCATGC
OAN2504 CTTGAAGCTTAGACATGGTGAGCAAGGGC
OAN2505 GGCTGGATCCTCAATTGTTTTTTCTCAGCTGAATAATTTTGATAAAGGCG
CCCAGGGAGAACACGCCAATAGCCAGCATGGCGAGAATCAGCTTGTACAG
CTCGTCCATG
OAN2518 AGATGAGCTAGCATGTCCGTCCTGACG
OAN2519 AGATGAAAGCTTTCAGATCTTCTTCAGAGATGAGTTTCTGCTCAGGGCCG
GGATTCTCCTCCACGTCACCGCATGTTAGAAGACTTCCTCTGCCCTCACC
GAGCAAAGAGTGGG
OAN2675 TCATCTCTCGAGTTATGTGGGGCCCCAGGC
OAN2272 CACCGCCTTGATGAGCCGCTCCCAA
OAN2273 AAACTTGGGAGCGGCTCATCAAGGC
OAN2569 AGATGACTCGAGATGTTTGGCCCCGCTAAAG
OAN2570 TCATCTAAGCTTCACTTCTCCAAAGTTGGTATGGC
OAN2571 AGATGACTCGAGATGGAAACATTACATATAATTTATTCAGAAGCAAAGTC
TTTTACAGTGGAGGGGCTGTCCAGCCGG
OAN2656 AGATGACATATGTTTGGCCCCGCTAAAG
OAN2657 AGATGACTCGAGATGGAAACATTACATATAATTTATTCAGAAGCAAAGTC
TTTTACAGTGGAGGGGCTGTCCAGCCGG
OAN2658 AGATGACATATGGAAACATTACATATAATTTATTCAGAAGC
OAN2661 TCATCTAAGCTTACGTTTAGTAAATGCAGGTGAACTTCTG
OAN2662 AGATGACTCGAGATGGAAACATTACATATAATTTATTCAGAAGCAAAG
OAN2663 AGATGACTCGAGATGGGTGCTTCTAGTTACGTCAGGGAA
OAN2664 AGATGACTCGAGATGTTCCCTGATCCAGATACACCTCC
OAN2665 AGATGACTCGAGATGACCCTGAGATGCATGGTATGTCA
Table 6: Oligonucleotides used in this study were purchased from Sigma-Aldrich.
4.1.2.5 Plasmids
Name Description
Vector Insert
pAN940 YFP-Parkin
gift from Richard Youle
pAN941 mcherryParkin
gift from Richard Youle
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pGBKT7 GAL4BD (bait)
Matchmaker (Clontech)
pGADT7 GAL4AD (prey)
Matchmaker (Clontech)
pAN3198 mKeima (Addgene #56018)
gift from Michael Davidson
pAN2741 FLAGUBXD1
pcDNA3.1+-DYK UBXD1 (Genscript: OHu09321)
pAN2861 YFP-UBXD1
EYFP-C1 (Clontech) pAN2741 PCR: OAN2020/2021
pAN2862 FLAGUBXD1DPUB
pcDNA3.1 *EcoRI, HindIII pAN2741 PCR: OAN2022/2025 *EcoRI, HindIII
pAN2863 FLAGUBXD1DUBX
pcDNA3.1 *EcoRI, XhoI pAN2741 PCR: OAN2022/2024 *EcoRI, XhoI
pAN3104 FLAGUBXD1DVIM
pAN2741*HindIII, EcoRV pAN2741 PCR: OAN2412/14 *HindIII, EcoRV
pAN3105 FLAGUBXonly
pAN2741*EcoRV, HindIII pAN2741 PCR: OAN2413/14 *HindIII, EcoRV
pAN3307 FLAG-VIMonly
pAN2855 *EcoRI/XhoI pAN2741 PCR: OAN2022/2675 *EcoRI/XhoI
pAN3080 YFP-UBXD1-ActA
pAN2861 *XhoI, EcoRI pAN2861 PCR: OAN2333/2334 *XhoI, EcoRI
pAN3187 YFP-ActA
pcDNA3 *BamHI, HindIII YFP-C1 PCR: OAN2504/2505 *BamHI, HindIII
pAN3090 GAL4BD-UBXD1
pGBTK7 *NdeI, BamHI pAN2861 PCR: OAN2398/9 *NdeI, BamHI
pAN3091 GAL4BD-UBXD1DPUB
pGBTK7 *NdeI, NotI pAN2862 PCR: OAN2400/01 *NdeI,NotI
pAN3092 GAL4BD-UBXD1DUBX
pGBTK7 *NdeI, BamHI pAN2863 PCR : OAN2400/02 *NdeI, BamHI
pAN3093 GAL4BD-UBXD1DVIM
pGBTK7 *NdeI, BamHI pAN2861 PCR: OAN2403/2399 *NdeI, BamHI
pAN3094 GAL4BD-UBXonly
pGBTK7 *NdeI, BamHI pAN2861 PCR: OAN2404/2399 *NdeI, BamHI
pAN3103 mitoYFP-T2A-3xmycParkin
pAN940*NheI, HindIII mitoYFP PCR: OAN2415/2416 *NheI, HindIII
pAN3216 mKeima-T2A-3xmycParkin
pAN940 *NheI, HindIII pAN3198: OAN2518/2519 *NheI, HindIII
pX45945 pSpCas9(BB)-2A-Puro (Addgene # 48139)
gift from Feng Zhang
pAN3046 UBXD1-CRISPR/Cas9
pX459 *BbsI Annealed OAN2272/2273
pAN3225 Homo sapiens YOD1 cDNA
pCR-XL-TOPO BC137167-seq-TCHS1003-GVO-TRI Biocat
pAN3238 YOD1isoform 1-mCherry
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mCherry-N1*XhoI, HindIII pAN3225 PCR: OAN2569/70 *XhoI, HindIII
pAN3239 YOD1isoform 2-mCherry
pmCherry-N1*XhoI, HindIII pAN3225 PCR: OAN2571/70 *XhoI, HindIII
pAN3283 pGBTK7-YOD1-1 full length
pGBTK7 *NdeI, BamHI pAN3238 PCR: OAN2656/57 *NdeI, BamHI
pAN3284 pGBTK7-YOD1-2 full length
pGBTK7*NdeI, BamHI pAN3239 PCR: OAN2658/57 *NdeI, BamHI
pAN3285 pGADT7-YOD1-1 full length
pGADT7*NdeI, BamHI pAN3238 PCR: OAN2656/57 *NdeI, BamHI
pAN3286 pGADT7-YOD1-2 full length
pGADT7 *NdeI, BamHI pAN3239 PCR: OAN2658/57 *NdeI, BamHI
pAN3292 YOD1-1 aa 1-136-mCherry
pAN3238 *XhoI, HindIII pAN3238 PCR: OAN2569/2661 *XhoI, HindIII
pAN3293 YOD1-2 aa 1-92-mCherry
pAN3238 *XhoI, HindIII pAN3239 PCR: OAN2662/2661 *XhoI, HindIII
pAN3294 YOD1 aa 93-304-mCherry
pAN3238 *XhoI, HindIII pAN3239 PCR: OAN2663/2570 *XhoI, HindIII
pAN3295 YOD1 aa 231-304-mCherry
pAN3238 *XhoI, HindIII pAN3239 PCR: OAN2664/2570 *XhoI, HindIII
pAN3296 YOD1 aa 273-304-mCherry
pAN3238 *XhoI, HindIII pAN3239 PCR: OAN2665/2570 *XhoI, HindIII
pAN3297 YOD1-1 - 3xFLAG
pAN3238 *BamHI, NotI Annealed OAN2666/7
pAN3298 YOD1-2 - 3xFLAG
pAN3239 *BamHI, NotI Annealed OAN2666/7
pAN3300 YOD1-1 - mCherry-ActA
pAN3238 *BamHI, NotI pmCherry-N1 PCR: OAN2668/9 *BamHI, NotI
pAN3301 YOD1-2 - mCherry-ActA
pAN3239 *BamHI, NotI pmCherry-N1 PCR: OAN2668/9 *BamHI, NotI
Table 7: Plasmids used in this study.
4.2 Methods
4.2.1 Molecular biological methods
4.2.1.1 Bacterial strains The Escherichia coli (E. coli) strains DH5α and
dam-/dcm- E. coli were used for cloning as well as ampliﬁcation of plasmid DNA. Both
strains were grown in Luria-Bertani media (LB) and on LB agar plates supplemented
with the appropriate antibiotic for selection. Antibiotics used were ampicillin (100 µg
/ml) or kanamycin (50 µg/ml).
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4.2.1.2 Preparation of chemically competent E. coli 6 ml of 2YT medium were
inoculated with either DH5αor dam-/dcm- E. coli strain and grown overnight. This
culture was diluted 1:100 in 10 ml 2YT medium and grown to OD600 = 0.5. This new
culture was diluted 1:100 in 100 ml 2YT medium, grown again until OD600 = 0.5 and
then chilled for 10 minutes in an ice-water bath. Bacteria were spun down in a pre-cooled
centrifuge at 2000 g and 4 °C for 7 minutes. The pellet was resuspended in ice-cold
transformation buﬀer 1 and chilled in an ice-water bath for 10 minutes. Bacteria were
again spun down in a pre-cooled centrifuge at 2000 g and 4 °C for 7 minutes, and the pellet
was resuspended in 2 ml of ice-cold transformation buﬀer 2. The bacterial suspension
was aliquoted on dry ice in 50 µl increments and immediately stored at -80 °C.
4.2.1.3 Preparation of electrocompetent E. coli DH5α or dam-/dcm- E. coli
were grown overnight in 6 ml LB medium and used to inoculate 400 ml LB medium at
1:100. This new culture was grown until OD600=0.5 and then chilled for 20 minutes in an
ice-water bath. Bacteria were spun down in a pre-cooled centrifuge at 2000 g and 4 °C
for 20 minutes. The bacterial pellet was resuspended in 400 ml ice-cold water and spun
down again in a pre-cooled centrifuge at 2000 g and 4 °C for 10 minutes. After repetition
of this washing step for a total of two washes, the bacterial pellet was resuspended in 1
ml of ice-cold LB medium containing 10 % glycerol. 50 µl aliquots were prepared on dry
ice and immediately stored at -80 °C.
4.2.1.4 Polymerase chain reactions (PCR) Polymerase chain reaction is a
method for exponential ampliﬁcation of a deﬁned DNA-sequence by a thermo stable
DNA-polymerase [248].
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component PCR1 PCR2 PCR3 PCR4
template (< 250 ng) 1 µl 1 µl 1 µl 1 µl
oligonucleotide 1 (10 µM) 2.5 µl 2.5 µl 2.5 µl
oligonucleotide 2 (10 µM) 2.5 µl 2.5 µl 2.5 µl
dNTPs (2 mM each) 5 µl 5 µl 5 µl 5 µl
5x HF buﬀer 5 µl 5 µl - -
5x GC buﬀer - - 5 µl 5 µl
DMSO - 1.5 µl - 1.5 µl
Phusion polymerase 0.5 µl 0.5 µl 0.5 µl 0.5 µl
water ad 50 µl ad 50 µl ad 50 µl ad 50 µl
Table 8: Pipetting scheme for optimization of DNA ampliﬁcation using Phusion poly-
merase. For DNA cloning purposes, DNA was ampliﬁed by PCR using high ﬁdelity
Phusion polymerase. Four diﬀerent conditions were tested. The condition with the most
optimal DNA ampliﬁcation was chosen for further processing.
temperature time
1x 98 °C 30 s
35x 98 °C 15 s
annealing 30 s
68 °C 60s/kb
1x 10 °C ∞
Table 9: Temperature proﬁle for DNA ampliﬁcation using Phusion polymerase. The
annealing temperature was chosen based on the recommendation the web-based NEB tm
calculator (https://tmcalculator.neb.com). PCR ampliﬁed DNA was separated from free
oligonucleotides through agarose gel electrophoresis and puriﬁed using NucleoSpin Gel
and PCR Clean-Up according to the manufacturer's recommendations.
4.2.1.5 DNA digestion For cloning purposes, plasmid DNA was treated with re-
striction enzymes. To this end, between 0.5 and 5 µg of plasmid DNA was treated with
1 to 10 U of restriction enzyme for at least 1 h at the manufacturer recommended tem-
perature and buﬀer conditions. DNA obtained through PCR ampliﬁcation was digested
overnight to improve digestion at the 5' and 3' ends. Whenever possible and were indi-
cated, double digestion using two or more restriction enzymes were performed according
to the manufacturer's instructions. Digested DNA was puriﬁed using agarose gel elec-
trophoresis (4.2.1.9) followed by Machery and Nagel's NucleoSpin Gel and PCR Clean-Up
kit.
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4.2.1.6 DNA ligation For DNA ligations, vector DNA and insert DNA obtained
by DNA digestion (4.2.1.5) were mixed at a 1:3 ratio, 1 µl of T4 DNA ligase and 2 µl
of the appropriate buﬀer (Thermo Fisher Scientiﬁc) in a total reaction volume of 20 µl
were added. The ligation mix was incubated at room temperature overnight, which was
followed by transformation into DH5α or dam-/dcm- E. coli (4.2.1.7).
4.2.1.7 DNA transformation into chemically competent E. coli Competent
DH5α or dam-/dcm- E. coli were thawed on ice. 3 µl of DNA ligation mix (4.2.1.6) was
added to 40 µl of competent bacteria and incubated for 30 minutes on ice. Heat shock
was carried out by incubating the reaction mix for 45 seconds at 42 °C, immediately
followed by cooling for 2 minutes on ice. The transformed bacteria were resuspended in
900 µl SOC medium and shaken at 700 rpm and 37 °C in a Thermomixer. An aliquot
of the transformation mix was spread on LB plates containing an appropriate antibiotic
and incubated at 37 °C overnight.
4.2.1.8 DNA plasmid isolation After DNA transformation, several E.coli clones
grown on LB plates were picked for veriﬁcation. Each clone was used to inoculate 5
ml of LB medium containing the appropriate antibiotic and incubated overnight at 37
°C and 250 rpm. Machery-Nagel's NucleoSpin Plasmid kit was used to isolate plasmid
DNA. DNA digestion (4.2.1.5) with appropriate restriction enzymes followed by agarose
gel electrophoresis (4.2.1.9) was performed to select correct clones. Correct clones were
veriﬁed by sequence analysis (Microsynth, Basel, CH).
4.2.1.9 Agarose gel electrophoresis Agarose gels were prepared from 0.7 % (w/v)
agarose diluted in 50 ml TAE buﬀer supplemented with 0.5 µg/ml ethidium bromide.
Plasmid DNA was mixed with DNA loading dye, and gel electrophoresis was carried out
at 85 V for 45 minutes. For puriﬁcation of DNA fragments, NucleoSpin Gel and PCR
Clean-Up kit (Machery-Nagel) was used according to manufacturer's recommendations.
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4.2.1.10 Phosphatase treatment of DNA Vector DNA for ligation reactions was
treated with shrimp alkaline phosphatase (SAP) to minimize vector religation. After
DNA digestion of plasmid DNA (4.2.1.5) and before puriﬁcation, 1 µl of TSAP with 2
µl of 10x buﬀer was added to the reaction mix and incubated at 37 °C for 15 minutes.
SAP was inactivated by incubation at 74 °C for 15 minutes. The reaction product was
puriﬁed via agarose gel electrophoresis (4.2.1.9) followed by Machery-Nagel's NucleoSpin
Gel and PCR Clean-Up kit.
4.2.1.11 Yeast two hybrid In a Matchmaker GAL4-based two-hybrid assay, a bait
protein is expressed as a fusion to the Gal4 DNA-binding domain (DNA-BD), while
libraries of prey proteins are expressed as fusions to the Gal4 activation domain. The
essay is based on the reconstitution of a functional transcription factor when two proteins
or polypeptides of interest interact (Figure 5). This takes place in genetically modiﬁed
yeast strains, in which the transcription of a reporter gene leads to a speciﬁc phenotype,
usually growth on a selective medium or change in the color of the yeast colonies [249]. A
downstream analysis in order to quantify the eﬀects of point mutations on the strength
of interaction was used. In this way, the Gal-responsive LacZ gene (b-galactosidase)
integrated in Y187 was implemented as a reporter for quantitative studies of protein-
protein interactions because has in this strain expresses strongly.
4.3 Biochemical methods
4.3.1 Preparation of cell lysates
Cells were harvested and cell pellets were stored on ice for immediate use or at -80 °C
for several days. For lysis, pellets were resuspended in RIPA buﬀer supplemented with
protease inhibitor cocktail and incubated on ice for 15 minutes. After incubation on
ice, samples were centrifuged at 14000 g for 15 minutes. Supernatants were mixed with
2x Laemmli sample buﬀer supplemented with 50mM DTT and heated to 95 °C for 10
minutes.
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Figure 5: The yeast-two-hybrid (Y2H) principle. Two proteins are expressed separately, one (a bait
protein) fused to the Gal4 DNA-binding domain (BD) for YOD1 (both isoforms) and the other (a
prey protein) fused to the Gal4 transcriptional activation domain (AD) p97 and UBXD1.
4.3.2 Measurement of protein content
During preparation of cell lysates (4.3.1), 10 µl of the supernatant obtained after cen-
trifugation were removed and diluted 1:10 in ddH2O. This diluted sample was used to
measure protein content using the Pierce BCA protein assay kit (Thermo Fisher Scien-
tiﬁc) according to manufacturer's recommendations. Brieﬂy, 25 µl of sample and eight
BCA reference solutions were added in triplicate to a 96 well plate. 200 µl of BCA Work-
ing Reagent was added to each well, followed by incubation at 37 °C for 30 minutes.
Absorption at 562 nm was measured on an ELISA reader to calculate protein content of
the sample.
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4.3.3 SDS PAGE
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a method used
to distribute proteins on an acrylamide gel according to their size. Gels consisting of a
4 % (w/v) acrylamide stacking gel overlaid on a 7 %, 9 % or 12 % (w/v) acrylamide
resolving gel were prepared in plastic 1.5 mm gel cassettes. Samples loaded onto the gels
were separated at 120 V for 110 minutes in Laemmli running buﬀer.
0.5 M Tris/HCl pH 6.8 2.5 ml
10 % SDS 100 µl
30 % acrylamide 1340 µl
10 % APS 200 µl
TEMED 10 µl
ddH2O 6 ml
Table 10: Preparation of stacking gels for SDS-PAGE.
component for 7 % gels 9 % gels 12 % gels
1.5 M Tris/HCl pH 8.8 5 ml 5 ml 5 ml
10 % SDS 200 µl 200 µl 200 µl
30 % acrylamide 4.7 ml 6 ml 8 ml
10 % APS 135 µl 135 µl 135 µl
TEMED 13 µl 13 µl 13 µl
ddH2O 10 ml 8.7 ml 6.7 ml
Table 11: Preparation of gels with diﬀerent resolving power for SDS-PAGE.
4.3.4 Western blotting
Western blotting is a method to transfer proteins from an SDS-PAGE gel to a nitrocel-
lulose membrane and was performed on a Trans-Blot SD Semi-Dry Transfer Cell (Bio-
Rad). After blotting, nitrocellulose membranes were blocked in PBS-T containing 3 %
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(w/v) TopBlock for 1 h to reduce nonspeciﬁc antibody binding. Primary antibody was
added to the membranes in PBS-T/TopBlock and incubated with gentle shaking at 4
°C overnight. After three washes in PBS-T, secondary HRP-coupled antibody diluted in
PBS-T/TopBlock was added to the membrane and incubated with gentle shaking for 2 h,
after which the membrane was washed three times with PBS-T. Proteins were detected
using a chemiluminescent substrate.
4.3.5 Immunoprecipitation
Cells were lysed for 20 min on ice using IP Buﬀer consisting of 50 mM Tris-HCl, pH
7.5, 150 mM NaCl, 2 mM ethylenediaminetetraacetic acid (EDTA), 0.75 % NP40. After
centrifugation (14000 g; 10 min; 4 °C) supernatant was collected and immunoprecipita-
tion assays were performed. Supernatant was incubated with anti-myc antibody against
3xmyc-tagged p97 for 2 h at 4 °C under constant rotation following immobilization onto
A/G PLUS Agarose Beads for 2h at 4 °C. After seven washing steps with IP buﬀer, SDS
page was performed according to a standard protocol. The following antibodies were
used for detection: mouse α-p97 (1:3000); rabbit α-FLAG (1:3000); mouse α-GAPDH
(1:3000); anti-rabbit HRP (1:20000); anti-mouse HRP (1:20000). Immunopuriﬁed pro-
teins were detected by Western blot.
4.3.6 Extraction of genomic DNA
Genomic DNA was extracted from cells using the GenElute Mammalian Genomic DNA
Miniprep kit according to the manufacturer's recommendations.
4.4 Cell Biology Methods
4.4.1 Cell culture
All cell lines were grown in a humidiﬁed incubator at 5 % CO2 and 37 °C. HeLa cells
were maintained in (Dulbecco's modiﬁed Eagle's media (DMEM)) supplemented with
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10 % fetal bovine serum (FBS), 1 mM sodium pyruvate and 2 mM L-glutamine. Cells
were passaged after reaching 90 % conﬂuency by removing growth medium, washing
once with PBS and incubating with Trypsin/EDTA at 37 °C until cells had detached.
Trypsin/EDTA was inactivated by adding medium 1:1. The solution was centrifuged at
1000g for 3 minutes and the cell pellet was re-suspended in fresh medium. Cells were
distributed into new tissue culture containers as required. For western blot experiments
and ﬂow cytometry, cells were grown in tissue culture dishes. For single cell cloning
experiments, cells were grown in 96 well tissue culture plates. For immunocytochemistry,
cells were grown on circular coverslips suspended in 6 well tissue culture plates. To
induce mitophagy, HeLa cells were treated with 50 µM carbonyl cyanide m-chlorophenyl
hydrazine (CCCP)
4.4.2 Induction of mitophagy
For measurements of mitochondrial membrane potential via ﬂow cytometry induction
of mitophagy and Parkin recruitment, cells were treated where applicable with 50 µM
CCCP for 12 hours before measurement.
4.4.2.1 Transfection of mammalian cells For confocal microscopy, cells were
transfected with Fugene 6. Cells were grown on circular coverslips suspended in 6 well
tissue culture plates or on Nunc Lab-Tek chamber slides. After 24 h at approximately
60 % conﬂuency, cells were transfected as follows. 3 µl Fugene 6 was added to 100 µl
Opti-MEM in an Eppendorf Safe-Lock tube while minimizing direct contact of Fugene 6
to plastic surfaces. After incubation at room temperature for 5 minutes, 1 µg of plasmid
DNA was added to the solution, which was incubated for another 15 minutes at room
temperature. Finally, the solution was added dropwise to the cells. 24 h after trans-
fection, cells were either ﬁxed for immunocytochemistry. All other transfections were
done using linear polyethylenimine (PEI). PEI MAX 40000 was dissolved 0.1 % (w/v) in
ddH2O adjusted to pH 7 with NaOH and stored at 4 °C. Cells were grown for 24 h before
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transfection with PEI [250]. PEI and plasmid DNA were added to Opti-MEM in a ratio
of 2:1. The solution was incubated at room temperature for 30 minutes and added to
the cells. After 4 h the medium was exchanged. Cells were grown for an additional 24 h
before obtaining lysates.
4.4.2.2 Knockdown of UBXD1 using CRISPR/Cas9 CRISPR consists of two
components: a guideRNA (gRNA) and a non-speciﬁc CRISPR-associated endonuclease
(Cas9). The gRNA is a short synthetic RNA composed of a scaﬀold sequence necessary
for Cas9-binding and a user-deﬁned 20 nucleotide targeting sequence which deﬁnes the ge-
nomic target to be modiﬁed. CRISPR was originally employed to knock-out target genes
in various cell types and organisms, but modiﬁcations to the Cas9 enzyme have extended
the application of CRISPR to selectively activate or repress target genes, purify speciﬁc
regions of DNA, and even image DNA in live cells using ﬂuorescence microscopy. The ge-
nomic target can be any 20 nucleotide DNA sequence, provided it meets two conditions:
The sequence is unique compared to the rest of the genome and the target is present
immediately upstream of a protospacer adjacent motif (PAM). The PAM sequence is ab-
solutely necessary for target binding and the exact sequence is dependent upon the species
of Cas9 (5' NGG 3' for Streptococcus pyogenes Cas9) (Figure 6). Once expressed, the
Cas9 protein and the gRNA form a riboprotein complex through interactions between the
gRNA scaﬀold domain and surface-exposed positively-charged grooves on Cas9. Cas9
undergoes a conformational change upon gRNA binding that shifts the molecule from
an inactive, non-DNA binding conformation, into an active DNA-binding conformation.
The Cas9-gRNA complex will bind any genomic sequence with a PAM, but the extent
to which the gRNA spacer matches the target DNA determines whether Cas9 will cut.
Once the Cas9-gRNA complex binds a putative DNA target, a seed sequence at the 3'
end of the gRNA targeting sequence begins to anneal to the target DNA. If the seed and
target DNA sequences match, the gRNA will continue to anneal to the target DNA in a
3' to 5' direction. In this study, using CRISPR/Cas9, UBXD1 was targeted in HeLa cells
and several alleles of UBXD1 were replaced with a reporter cassette coding for secreted
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Figure 6: Schematic representation of CRISPR/Cas9 strategy for UBXD1 knockdown. Using
CRISPR/Cas9, UBXD1 was targeted in HeLa cells and several alleles of UBXD1 were replaced with a
reporter cassette coding for secreted Gaussia luciferase. Each gRNA needs homology arms (use 800
bp immediately CRISPR tream and downstream of the target). CMV promoter and Gluc gene were
knock in for fast screening of single clones.
Gaussia luciferase. Gaussia luciferase is secreted into the cell culture media and the light
output generated by the luciferase reaction can be correlated to the amount of Gaussia
luciferase protein produced. In this way the activity of the promoter driving Gaussia
expression was measured. PCR analysis and western blot (anti-UBXD1) were performed
to conﬁrm knockdown of UBXD1.
4.4.2.3 Immunocytochemistry Cells grown on circular coverslips suspended in 6
well tissue culture at a density of 30000 cells per well and where applicable transfected or
treated were washed once in PBS. Cells were suspended in 4 % paraformaldehyde / PBS
for 15 minutes at room temperature. Cells were washed again in PBS and suspended in
0.15 % Triton X 100 / PBS for 15 minutes at room temperature. Cells were re-suspended
in 10 % bovine serum albumine (BSA)/PBS for 1 h. The primary antibody was added as
indicated in 10 % BSA/PBS and cells were incubated at 4 °C overnight. Cells were washed
three times in 10 % BSA/PBS, and the secondary antibody was added as indicated in 10
% BSA/PBS. Cells were incubated at room temperature for 2 h and ﬁnally washed three
times in PBS before being mounted on Superfrost microscope slides with Vectashield
mounting medium.
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4.4.2.4 Confocal microscopy Confocal images were obtained on a Visitron, Spin-
ning Disk, confocal laser scanning microscope ﬁtted with 405 nm, 458 nm, 488 nm, 514
nm, 543 nm and 633 nm laser lines using 63x/1.40 oil DIC objective.
4.4.2.5 Image analysis Image analysis was done using the Fiji distribution of Im-
ageJ [251].
4.4.2.6 Flow cytometric analysis of mitophagy HeLa cells were grown in 10cm
culture plates and transfected with mKeima and Parkin (mKeima-T2A-3xmycParkin) as
well as UBXD1 or control vector were treated with CCCP or left untreated as indi-
cated. 24 h after induction and treatment, cells were harvested using Trypsin/EDTA,
washed with PBS and equal numbers of cells for each condition were transferred to
Eppendorf Safe-Lock tubes. Cells were gated to exclude debris (FlowJo) and cells
not expressing mKeima (488 nm). To quantify mitophagy, cells expressing mKeima
and transfected with vector control without CCCP treatment were used to establish
mKeima561nm/mKeima488nm threshold. Using R, a linear model was established based
on the mean of the 99th percentile mKeima561nm for each mKeima488nm value using
the R quantreg package. Cells above the mKeima561nm/mKeima488nm threshold were
counted to determine percentage of cells with above control mitophagy levels.
4.4.2.7 Assessing cytochrome release HeLa cells grown in Nunc Lab-Tek chamber
slides, ﬁxed and stained with mouse anti cytochrome c and anti mouse Alexa546-labeled
antibodies. Cells were assessed in a blinded manner by confocal microscopy. Apoptosis
is accompanied by the release of mitochondrial cytochrome c into the cytosol. Therefore,
randomly chosen YFP-positive cells were classiﬁed after their cytochrome c localization
as either sharply deﬁned mitochondrial or unspeciﬁc cytosolic.
4.4.2.8 Statistical methods All experiments were performed independently at least
three times. Statistical signiﬁcance was assessed by ANOVA with posthoc two-tailed Stu-
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dent's t-test using Bonferroni or Holm adjustment to account for multiple comparisons.
P-values > 0.05 are marked with n.s., p < 0.05 with *, p < 0.01 with **, p < 0.001 with
***.
5 Results
5.1 Identiﬁcation of p97 cofactors involved in mitochondrial
maintenance
Failing mitochondrial quality control is connected to aging and neurodegeneration [43].
Mounting evidence connects the UPS with mitochondrial maintenance [252, 253] in a
process termed OMMAD. Recently, the ATPase associated with various cellular activities
(AAA-ATPase) p97 was connected to OMMAD and likely constitutes the retrotranslocase
for the extraction of mitochondrial proteins for proteasomal degradation in the cytosol
[254, 255]. Furthermore, p97 was recently connected to the execution of mitophagy,
another important mitochondrial quality control pathway [254]. As diverse p97 functions
are governed by interaction with a plethora of cofactors, the mitochondrial translocation
of UBX domain-containing p97 cofactors under mitophagic conditions was investigated
to elucidate the cofactor requirements of p97 to perform its function at the interface
between OMMAD and mitophagy.
5.1.1 Subcellular localization of p97 cofactors under mitophagic conditions
In order to identify mitochondrial cofactors of p97, a list of all known and suspected p97
cofactors was compiled (Table 12). Thirteen proteins with known or suspected connec-
tion to p97 were identiﬁed. Except for Ufd1 and Npl4, no mitochondrial function was
suggested in the literature so far [256] . For all candidates except Ufd1 and Npl4, open
reading frames were obtained and cloned into mammalian expression vector pcDNA3.1*-
DYK leading to the expression of FLAG epitope-tagged protein. Subsequent transfection
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name Gene ID localization localization CCCP/Parkin
UBXN8 7993 ER ER
UBXN7 26043 Nucleus Nucleus
UBXN9 79058 Cytosol Cytosol
Derlin-1 79139 ER ER
UBXD5 91544 ER ER
VIMP 55829 ER ER
UBXD3 127733 Cytosol Cytosol
UBXD4 165324 Cytosol Cytosol
UBXD1 80700 Cytosol mitochondrial
SAKS1 (UBXN1) 51035 Cytosol mitochondrial
Erasin (UBXN4) 23190 ER mitochondrial
Table 12: UBX-domain containing p97 cofactors analyzed for mitochondrial
localization. Eleven p97 cofactors were cloned as FLAG fusion proteins and their sub-
cellular localization under normal and mitophagic conditions (co-transfection with Parkin
and CCCP treatment) was determined.
of these expression constructs into HeLa cells together with mcherryParkin followed by
staining for FLAG-tagged p97 cofactors revealed in the absence of the mitophagic in-
ducer CCCP staining patterns typical for cytosolic, nuclear or ER localization (Table
12, Figure 7). Upon addition of CCCP for 6 h three of the eleven p97 cofactors ana-
lyzed displayed co-localization with mcherryParkin. As CCCP induces the translocation of
Parkin to mitochondria, this was indicative for a potential mitochondrial translocation
of UBXD1, SAKS1 and Erasin under mitophagic conditions.
5.1.2 Localization of p97 cofactors UBXD1, SAKS1, and Erasin
To conﬁrm the suspected mitochondrial translocation of UBXD1, SAKS1, and Erasin
under mitophagic conditions, subcellular colocalization studies between FLAG-tagged
UBXD1, SASK1, and Erasin and mitochondria-targeted mitoDsRed were performed (Fig-
ure 8). While all three cofactors did not colocalize with mitoDsRed in the absence of
CCCP, following induction of mitophagy by addition of CCCP UBXD1, SAKS1, and
Erasin displayed overlap with mitoDsRed in YFP-Parkin expressing cells. This data
strongly suggested an involvement of UBXD1, SAKS1, and Erasin together with their
eﬀector p97 in mitophagy.
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Figure 7: HeLa cells were transfected with eleven known p97 cofactors constructs for mitochondrial
matrix-targeted Parkin Cherry (red) expression, treated for 6 h with 50 µM CCCP to induce mitophagy
or left untreated as control. Fixed cells were stained using anti-FLAG antibodies (green) and imaged
by confocal microscopy. Please note the no localization of any of these twelve candidate proteins on
mitochondria upon CCCP treatment.
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Figure 8: HeLa cells were transfected with expression constructs for mitochondrial matrix-targeted
mitoDsRed (red), YFP-Parkin (green), FLAG-tagged UBXD1, SAKS1 or Erasin, treated for 6 h with
50 µM CCCP to induce mitophagy or left untreated as control. Fixed cells were stained using anti-
FLAG antibodies (blue) and imaged by confocal microscopy. Please note the localization of these
three p97 cofactors together with Parkin towards mitochondria upon CCCP treatment.
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Figure 9: Expression of mitochondrial p97 cofactors UBXD1, SAKS1, and Erasin in HeLa cells. HeLa
cells were harvested and total RNA was extracted. Levels of UBXD1, SAKS1, Erasin and β-actin
were determined by qRT-PCR. Shown are boxplots (three biological with three technical replicates)
of Δct-values for the expression level of UBXD1, SAKS1 and Erasin relative to β-actin expression
levels.
In order to better assess HeLa cells as a model for studying mitochondrial cofactors of p97,
the expression of UBXD1, SAKS1 and Erasin were analyzed by quantitative RT-PCR.
As shown in Figure 9, all three p97 cofactors are expressed in HeLa cells.
5.2 Combined expression of mitochondria-targeted YFP and
Parkin using T2A peptide fusion
HeLa cells do not express Parkin, thus, studying Parkin-mediated mitophagy necessi-
tates the ectopic expression of this ubiquitin ligase. In this study, the simultaneous ec-
topic expression of more than one gene was necessary. To this end, a gene fusion between
mitochondria-targeted YFP and 3xmycParkin separated by a T2A sequence was generated.
Upon translation of the fusion gene, the ribosome co-translationally cleaves the T2A pep-
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tide resulting in the production of two polypetides from one mRNA [257, 258]. To assess
whether mitoYFP-T2A-3xmycParkin was indeed cotranslationally processes, HeLa cells
were transfected with an expression plasmid for mitoYFP-T2A-3xmycParkin treated with
CCCP or left untreated and stained using anti-myc antibodies. As shown in Figure 10,
in the absence of CCCP mitoYFP displays a clearly mitochondrial pattern, while Parkin
resides in the cytosol. Upon addition of CCCP, Parkin translocates to mitochondria
as expected. Thus, mitoYFP-T2A-3xmycParkin is processed cotranslationally and Parkin
shows translocation to depolarized mitochondria.
5.3 Assessing the impact of CCCP treatment on cellular viability
CCCP causes the depolarization of mitochondria through proton shuttling across the
IMM while circumventing F0F1-ATPase. To establish that CCCP does not induce
unwanted cell death possibly confounding results, HeLa cells were transfected with
mitoYPF-T2A-3xmycParkin and treated with 0, 10, 25, and 50 µM CCCP for 12 and
24 h. Under these conditions, no release of cytochrome c was observed (Figure 11).
Thus, the employed CCCP concentrations to induce mitochondrial depolarization and
mitophagy did not cause apoptotic cell death.
5.4 Dependency of UBXD1 translocation on CCCP concentra-
tion
The p97 cofactor UBXD1 translocates to mitochondria under mitophagic conditions. To
further characterize this shift in subcellular localization, UBXD1 translocation in Parkin
expressing cells was assessed in cells treated with increasing concentrations of CCCP.
As shown in Figure 12, treatment of cells expressing mitoYFP-T2A-3xmycParkin together
with FLAGUBXD1 revealed translocation of UBXD1 at all analyzed CCCP concentrations.
Interestingly, increasing CCCP concentrations caused increasingly eﬃcient translocation
of UBXD1 to mitochondria.
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Figure 10: Combined expression of mitochondria-targeted YFP and Parkin. (A) HeLa cells transfected
with an expression plasmid for mitodsRED and a fusion protein between mitoYFP and 3xmycParkin
separated with the cotranslationally-cleaved T2A peptide were analyzed by confocal microscopy after
treatment with CCCP for 6 h or no treatment as control. Note that mitoYFP and mitodsRED colo-
calize and that both markers show the typical CCCP-induced mitochondrial fragmentation. (B) HeLa
cells transfected with mitoYFP-T2A-3xmycParkin were treated with CCCP for 6 h or left untreated,
ﬁxed and stained using mouse anti-myc antibodies. Please note the lack of co-localization between
mitoYFP and 3xmycParkin in the absence of CCCP and the overlap of both mitoYFP and Parkin in
the presence of CCCP, conﬁrming intended cotranslational processing of mitoYFP-T2A-3xmycParkin.
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Figure 11: CCCP treatment does not induce apoptosis in HeLa cells. HeLa transfected with mitoYPF-
T2A-3xmycParkin were treated for 12 or 24 h with 0, 10, 25, or 50 µM CCCP, ﬁxed, stained using
anti-cytochrome c antibodies and analyzed by ﬂuorescence microscopy. Shown are representative
images of three independent experiments.
Figure 12: HeLa cells transfected with expression constructs for FLAGUBXD1 and mitoYFPT2A-
3xmycParkin were treated with 10, 15, 25, 40, or 50 µM CCCP for 6 h or left untreated as control.
Cells were ﬁxed, stained using mouse anti-FLAG antibodies to detect UBXD1 and analyzed by confocal
microscopy.
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Figure 13: UBXD1 translocates to depolarized mitochondria in a Parkin-dependent manner. HeLa
cells transfected with expression constructs for FLAGUBXD1, mitoYFP, and Parkin or vector control
were treated with 50 µM CCCP for 6 h of left untreated as control.
5.5 UBXD1 translocates to depolarized mitochondria in a
Parkin-dependent manner
To assess the Parkin-dependency of mitochondrial translocation of UBXD1, cells express-
ing FLAGUBXD1 in the presence or absence of Parkin were treated with 50 µM CCCP or
left untreated. As shown in Figure 13, in the absence of Parkin and CCCP, FLAGUBXD1
displays cytosolic localization and does not colocalize with the mitochondrial marker mi-
toYFP. However, in the presence of Parkin and following mitochondrial depolarization, a
proportion of UBXD1 translocates to mitochondria. These ﬁndings suggest that UBXD1
is able to recognize a signal which becomes apparent on depolarized mitochondria after
Parkin recruitment.
5.6 Mutational analysis of UBXD1
Cofactors of p97 are characterized by their modular structure consisting of protein
domains with known functions mediating interaction with p97 and ubiquitinated pro-
teins. To further characterize the connection of UBXD1 to mitochondria, FLAG-
tagged UBXD1 mutants lacking the VIM (UBXD1ΔVIM), PUB (UBXD1ΔPUB), UBX
(UBXD1ΔUBX), PUB and UBX (VIMonly) or VIM and PUB domain (UBXonly) were
generated (Figure 14).
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Figure 14: Schematic domain organization of wildtype UBXD1 and mutants used in this study.
UBXD1 contains with VIM, PUB and UBX three protein-protein interaction domains. Shown are
drawn to scale schematic representation of UBXD1 truncation mutants.
5.6.1 Protein-protein interaction domains in UBXD1
HeLa cells transiently coexpressing FLAGUBXD1 or mutants of FLAGUBXD1 together
with mitoYFP-T2A-3xmycParkin were treated with CCCP or left untreated. As shown
in Figure 15A, FLAGUBXD1 lacking VIM, PUB or both domains was still capable of
mitochondrial translocation, similar to wildtype FLAGUBXD1. Strikingly, FLAGUBXD1
without the UBX domain lacked mitochondrial localization even under mitophagic con-
ditions. To quantify UBXD1 mitochondrial translocation, the ratio of FLAGUBXD1 on
mitochondria to non-mitochondrial FLAGUBXD1 was determined (Figure 15B). In line
with the ﬁndings shown in Figure 15A, a signiﬁcant diﬀerence (p< 0.001) in the mito-
chondrial to total FLAGUBXD1 ratio (expressed as median ± median absolute deviation)
between control cells and cells treated with CCCP was found for wildtype FLAGUBXD1
(no CCCP: 1.11 ± 0.24; plus CCCP: 1.63 ± 0.4), FLAGUBXD1ΔPUB (no CCCP: 1.09±
0.1; plus CCCP: 1.92 ± 0.93), FLAGUBXD1ΔVIM (no CCCP: 1.04 ± 0.21; plus CCCP:
1.34± 0.47) and FLAGUBXonly (no CCCP: 1.12 ± 0.16; plus CCCP: 1.58 ± 0.61), but
not for FLAGUBXD1ΔUBX (no CCCP: 0.99 ± 0.22; plus CCCP: 1.04±0.21). These
data point to an UBX domain-dependent targeting of UBXD1 to mitochondria under
mitophagic conditions, while VIM and PUB domains, whether separate or in concert, are
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not suﬃcient to mediate mitochondrial translocation.
5.7 UBXD1 mediates mitochondrial recruitment of p97
As shown in Figure 15, the UBX domain of UBXD1 determines translocation to mito-
chondria under mitophagic conditions. Interestingly, the UBX domain is generally con-
sidered to confer binding to p97. However, UBXD1 is particular in this regard as it has a
complex interaction mode with p97 likely involving its VIM and PUB domains [158]. To
assess whether translocation of UBXD1 to mitochondria might also cause recruitment of
p97, mitochondrial translocation of p97 was studied.
5.7.1 UBXD1 recruits p97 to mitochondria under mitophagic conditions
Analyzing the distribution of endogenous p97 in cells co-expressing FLAGUBXD1 and
mitoYFP-T2A-3xmycParkin in the presence or absence of CCCP, a strong redistribution
of p97 from the cytosol to mitochondria upon addition of CCCP compared to controls
was found (Figure 16A). Quantitative image analysis (Figure 16B) conﬁrmed a signiﬁ-
cant (p<0.0001) accumulation of endogenous p97 on mitochondria in cells with ectopic
expression of FLAGUBXD1 under mitophagic conditions (plus FLAGUBXD1/plus CCCP:
2.01 ± 0.7) compared to control cells either with undisturbed mitochondrial membrane
potential (plus FLAGUBXD1/no CCCP: 1.15 ± 0.24) or lacking ectopic UBXD1 expres-
sion (no FLAGUBXD1/plus CCCP: 1.25 ± 0.31; no FLAGUBXD1/no CCCP: 1.21 ± 0.18).
These data are consistent with UBXD1 acting as p97 mitochondrial recruitment factor
under mitophagic conditions.
5.7.2 The UBX domain of UBXD1 is essential for mitochondrial transloca-
tion of p97
To further explore the potential role of UBXD1 in targeting p97 to mitochondria, redis-
tribution of endogenous p97 following expression of FLAGUBXD1 mutants was analyzed.
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Figure 15: VIM and PUB, but not the UBX domain of UBXD1 are dispensable for mitochondrial
translocation during mitophagy. (A) HeLa cells transfected with mitoYFP-T2A-3xmycParkin and
FLAGUBXD1, FLAGUBXD1ΔPUB, FLAGUBXD1ΔVIM, FLAGUBXD1ΔUBX, or FLAGUBXonly expres-
sion constructs were treated with CCCP 6 h or left untreated as control, stained using mouse anti-
FLAG antibodies and analyzed by confocal microscopy. (B) The ratio of mitochondrial to total
FLAGUBXD1 or various FLAGUBXD1 variants as measure for mitochondrial translocation was quanti-
ﬁed by image analysis of confocal pictures obtain from cells treated as in A. Shown are box plots of
three independent experiments with at least 15 cells per experiment and condition. Statistical signif-
icance was assessed by ANOVA followed by Student's t-test using Bonferroni correction to account
for multiple comparisons. *** denotes p-values < 0.001, n.s. - no signiﬁcant diﬀerence.
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Figure 16: UBXD1 recruits p97 to mito-
chondria under mitophagic conditions. (A)
HeLa cells transfected with expression plas-
mids for FLAGUBXD1 and mitoYFP-T2A-
3xmycParkin were treated with CCCP for 6 h
or left untreated as control. Cells were ﬁxed,
stained using rabbit anti-FLAG and mouse
anti-p97 antibodies and analyzed by confo-
cal microscopy. (B) HeLa cells transfected
with expression plasmids for FLAGUBXD1 or
vector control and mitoYFP-T2A-3xmycParkin
were treated as in A. To quantify p97 redis-
tribution to mitochondria, the ratio of mito-
chondrial p97 to total p97 was determined by
image analysis of confocal images. Shown are
box plots of three independent experiments
with at least 15 cells per experiment and con-
dition. Statistical signiﬁcance was assessed
by ANOVA followed by Student's t-test using
Bonferroni correction to account for multiple
comparisons. *** denotes p-values < 0.001.
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HeLa cells expressing mitoYFP-T2A-3xmycParkin together with wildtype FLAGUBXD1 or
FLAGUBXD1 mutants were treated with CCCP or left untreated as control, and ratios
of mitochondrial p97 to total p97 (p97m/p97t) and mitochondrial FLAGUBXD1 to total
FLAGUBXD1 (FLAGUBXD1m/ FLAGUBXD1t) were determined (Figure 17). Conﬁrm-
ing the previous ﬁndings, FLAGUBXD1 translocated to mitochondria under mitophagic
conditions via its UBX domain, while VIM and PUB domains did not contribute to
mitochondrial targeting. As for p97 recruitment, confocal microscopy and determination
of p97m/p97t revealed signiﬁcant mitochondrial enrichment of endogenous p97 under
mitophagic conditions compared to controls expressing FLAGUBXD1 (no CCCP: 1.18 ±
0.14; plus CCCP: 1.65 ± 0.29), FLAGUBXD1ΔPUB (no CCCP: 1.25 ± 0.14; plus CCCP:
1.62±0.47), and FLAGUBXD1ΔVIM (no CCCP: 1.23 ± 0.16; plus CCCP: 1.61 ±0.47),
but not in FLAGUBXD1ΔUBX (no CCCP: 1.18 ±0.17; plus CCCP: 1.10 ± 0.21) or
FLAGUBXonly (no CCCP: 1.15 ± 0.07; plus CCCP: 0.99 ± 0.1) expressing cells (Figure
17). These data are consistent with UBXD1 binding to depolarized, Parkin-containing
mitochondria via its UBX and recruiting p97 through its VIM and PUB domain.
5.7.3 VIM domain characterization
Analysis of UBXD1ΔVIM translocation (Figure 17) suggested a potential involvement
of the VIM domain in mitochondrial binding. To address this question, mitochondrial
translocation and p97 recruitment activity of the VIM domain (VIMonly) was analyzed.
HeLa cells expressing VIMonly and mitoYFP-T2A-3xmycParkin treated with CCCP or left
untreated showed neither translocation of VIMonly nor of p97 to mitochondria (Figure
18). These data are consistent with p97 recruitment to mitochondria via the VIM or PUB
domain upon binding of the UBX domain of UBXD1 to mitochondria. Thus, a direct
physical interaction between the VIM or PUB, but not the UBX domain of UBXD1 and
p97 would be expected.
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Figure 17: The UBX domain of UBXD1 is essential for mitochondrial translocation of p97. HeLa
cells transfected with expression plasmids for FLAGUBXD1 or variants of FLAGUBXD1 and mitoYFP-
T2A-3xmycParkin were treated with CCCP for 6 h or left untreated as control. Fixed cells were stained
using rabbit anti-FLAG and mouse anti-p97 antibodies and analyzed by confocal microscopy. The box
plots represent three independent experiments with at least 15 cells/experiment/condition. Statistical
signiﬁcance was assessed by ANOVA followed by Student's t-test using Bonferroni correction to
account for multiple comparisons. ** denotes p-values < 0.01, *** p-values < 0.001, n.s.  no
signiﬁcant diﬀerence.
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Figure 18: The VIM domain of UBXD1 is not involved in mitochondrial translocation and p97
recruitment. HeLa cells transfected with expression plasmid for FLAG-VIMonly and mitoYFP-T2A-
3xmycParkin were treated with CCCP for 6 h or left untreated as control. Fixed cells were stained
using rabbit anti-FLAG and mouse anti-p97 antibodies and analyzed by confocal microscopy. The box
plots represent three independent experiments with at least 15 cells/experiment/condition. Statistical
signiﬁcance was assessed by ANOVA followed by Student's t-test using Bonferroni correction to
account for multiple comparisons. n.s.  no signiﬁcant diﬀerence.
5.7.4 Mitochondrial UBXD1 is suﬃcient for p97 recruitment
To assess whether UBXD1 alone is suﬃcient to cause translocation of p97 to mito-
chondria, full-length YFPUBXD1 or YFP as control were targeted to the OMM through
a C-terminal ActA tail anchor. ActA is a surface protein of 639 amino acids, anchored
to the bacterial membrane Listeria monocytogenes inducing actin nucleation on the bac-
terial surface. The continuous process of actin ﬁlament elongation provides the driving
force for bacterial propulsion in infected cells or cytoplasmic extracts [259]. ActA, when
expressed in mammalian cells, is targeted to mitochondria via its C-terminal hydrophobic
tail [260].
As shown in Figure 19A , ActA tail targeted YFPUBXD1 as well as YFP to mitochondria
in the absence of ectopic Parkin expression or addition of CCCP. No signiﬁcant diﬀerence
in mitochondrial targeting between YFPUBXD1-ActA and YFP-ActA was observed (mito-
chondrial/total YFP  YFP-ActA: 2.09 ± 0.56, YFP-UBXD1-ActA: 1.77 ± 0.35 - Figure
19B). Interestingly, whereas endogenous p97 signiﬁcantly redistributed to mitochondria
in cells expressing YFP-UBXD1-ActA, p97 did not show this localization pattern in cells
expressing YFP-ActA (mitochondrial/total p97, YFP-ActA: 1.13 ± 0.08, YFP-UBXD1-
ActA: 1.3 ± 0.17, p = 0.0003). This observation suggests that the presence of UBXD1
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Figure 19: Induction of mitochondrial recruitment by ActA tail. HeLa cells transfected with ex-
pression plasmids for mitochondria-targeted dsRED (mitodsRED) and YFP-UBXD1 or YFP fused
to the mitochondrial membrane targeting signal ActA were ﬁxed, stained using mouse anti-p97 an-
tibodies, and analyzed by confocal microscopy. (A) Shown are representative images out of three
independent experiments. (B) The box plots represent three independent experiments with at least 15
cells/experiment/condition. Statistical signiﬁcance was assessed by by Student's t-test. *** denotes
p < 0.001, n.s.  no signiﬁcant diﬀerence.
on mitochondria is suﬃcient for the recruitment of p97 to this organelle.
5.7.5 Physical interaction of UBXD1 with p97
To elucidate the molecular basis underlying the UBXD1-mediated mitochondrial recruit-
ment of p97, we analyzed the contribution of all UBXD1 domains to a potential direct
physical interaction between UBXD1 and p97. First, co-immunopuriﬁcation and, second,
direct yeast two hybrid interaction analyses were performed.
5.7.5.1 Immunopuriﬁcation of p97 Co-Immunoprecipitation experiments of
p97 from cells co-expressing UBXD1, UBXD1ΔVIM, UBXD1ΔPUB, UBXonly, or
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Figure 20: Physical interaction
of UBXD1 with p97. Lysates
of HeLa cells expressing 3x-myc
epitope-tagged p97 together with
FLAGUBXD1, FLAGUBXD1ΔVIM,
FLAGUBXD1ΔPUB, FLAGUBXonly or
FLAGUBXD1ΔUBX were incubated
with mouse anti-myc antibodies and
protein A/G beads. Immunopuri-
ﬁed (IP) 3xmycp97 and co-purifying
FLAGUBXD1 variants were analyzed
by Western blotting. Detection of
GAPDH in whole cell lysates (WCLs)
served as loading control. Shown
are representative blots from three
independent experiments.
UBXD1ΔUBX revealed co-puriﬁcation of UBXD1, UBXD1ΔVIM, UBXD1ΔPUB, and
or UBXD1ΔUBX but not UBXonly with p97 (Figure 20). This data is consistent with
UBXD1 interacting with p97 via its VIM and PUB, but not its UBX domain.
5.7.5.2 Yeast two hybrid system To further conﬁrm and quantify the observed
interaction pattern between UBXD1 and p97 (Figure 20), yeast two hybrid analysis was
performed. This essay is based on the reconstitution of a functional transcription factor
when two proteins or polypeptides of interest interact. This takes place in genetically
modiﬁed yeast strains, in which the transcription of a reporter gene leads to a speciﬁc
phenotype, usually growth on a selective medium or change in the color of the yeast
colonies. The protein, which is fused to DNA-binding domain, was named the bait
and the protein which was fused to the activating domain was called the prey [249].
72
As shown in Figure 21, a serial dilution of yeast strains containing Gal4BD-UBXD1
or Gal4BD-UBXD1 mutants as bait and Gal4AD-p97 as prey or GAL4AD vector as
prey control on media selective for interaction (drop-out) revealed growth of strains
containing Gal4AD-p97 and Gal4BD-UBXD1, or Gal4BD-UBXD1ΔVIM, or Gal4BD-
UBXD1ΔPUB or Gal4BD-UBXD1ΔUBX. In contrast, no growth was detected for yeast
strains containing empty pGBKT7 bait or Gal4BD-UBXonly. A serial dilution growth
assay on media not selective for bait-prey interaction served as control. These data
conﬁrm a direct physical interaction between p97 and UBXD1 via its VIM and also
the PUB domain of UBXD1. To elucidate to which extent VIM and PUB domain of
UBXD1 contribute to the observed interaction between p97 and UBXD1, we performed
a quantitative yeast two-hybrid interaction assay (Figure 21B). We found no signiﬁ-
cant diﬀerence (p=0.13) in the interaction strength expressed as percentage of wildtype
GAL4BD-UBXD1 between GAL4AD-p97/GAL4BD-UBXD1ΔVIM (8.1 ± 2.8 %) and
GAL4AD-p97/GAL4BD-UBXD1ΔPUB (13.8 ± 3.8 %). Interestingly, the interaction
strength between GAL4AD-p97 and GAL4BD-UBXD1ΔUBX containing both PUB and
VIM domain is 29.2 ± 7.1 % of wildtype GAL4BD-UBXD1. Thus, both VIM and PUB
domain seem to contribute about equally to the physical interaction, and without obvious
cooperativity.
5.8 UBXD1 promotes mitophagy induction
Eﬃcient mitophagy relies on the engulfment of the damaged organelles into the forming
autophagosome, without aﬀecting the entire mitochondrial network [261]. Mitochondrial
network fragmentation is observed prior to mitophagy, allowing the eﬃcient uptake of
small, depolarized mitochondrial subunits into autophagosomes for lysosomal degrada-
tion. This mitochondrial fragmentation is triggered by the Parkin-mediated ubiquitina-
tion and the p97-dependent retrotranslocation and proteasomal degradation of the mito-
fusin Mfn2 [255]. Based on the UBXD1-dependent recruitment of p97, UBXD1 might be
a critical step for mitophagy onset and/or progression.
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Figure 21: Physical interaction of UBXD1
with p97. Cells of yeast strain Y2HGold
were transformed with expression constructs
for fusion proteins between UBXD1 and the
GAL4 DNA binding domain and p97 and
the GAL4 activation domain. Transformation
with pGADT7 (empty vector with GAL4 acti-
vation domain  labeled vector) or pGBKT7
(empty vector with GAL4 DNA binding do-
main  GAL4BD) served as control. Yeast
strains were serially diluted onto plates se-
lecting for expression plasmids (control) and
plates selecting for yeast two-hybrid interac-
tion (drop-out). (B) Strength of yeast two-
hybrid interaction between UBXD1 or vari-
ants of UBXD1 and p97 were quantiﬁed us-
ing a para-nitrophenyl-alpha-galactoside as-
say. Shown is the average of three indepen-
dent experiments with ﬁve independent yeast
transformands per condition. Error bars rep-
resent SD.
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Figure 22: UBXD1 promotes mitophagy. HeLa cells transfected with expression plasmids for
FLAGUBXD1 or vector control, mcherryParkin and LC3-GFP were ﬁxed, stained using mouse anti-
FLAG antibodies, and analyzed by confocal microscopy.
5.8.1 Increased mitophagy in cells expressing UBXD1
HeLa cells co-expressing FLAGUBXD1 and LC3-GFP in the presence of mcherryParkin were
treated with CCCP for 6 h and autophagic vesicle formation was observed. As shown in
Figure 22, LC3-GFP positive vesicle density near mitochondria was strongly increased
in FLAGUBXD1 expressing cells compared to controls. This observation is indicative of
UBXD1 acting in a pro-mitophagic fashion.
To analyze the impact of UBXD1 on mitophagy, mitophagic ﬂux in cells ectopically
expressing FLAGUBXD1 was measured. HeLa cells co-transfected with expression con-
structs for the pH-sensitive, mitochondria-targeted reporter mKeima fused to Parkin via
the ribosome-cleaved T2A peptide (mKeima-T2A-3xmycParkin) and UBXD1 or vector
control were treated for 12 h with CCCP to induce mitophagy and analyzed ﬂow cy-
tometrically. The ﬂuorescent reporter mKeima is excitable at 488 nm at pH 7 (inside
mitochondria) and 561 nm at pH 4 as encountered inside autolysosomes. Thus, the ratio
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Figure 23: Increased mitophagy after ectopic expression of UBXD1. HeLa cells transfected with
expression plasmids for UBXD1 or vector control and mKeima-T2A-3xmycParkin were treated for 12 h
with CCCP or left untreated and analyzed by ﬂow cytometry. Shown are representative density plots
(left panels). The box plot represents 6 independent experiments with in total 11 technical repli-
cates. Statistical signiﬁcance was assessed by ANOVA followed by Student's t-test using Bonferroni
correction to account for multiple comparisons. *** marks p-values < 0.001, n.s.  no signiﬁcant
diﬀerence.
mKeima561nm/mKeima488nm is a measure for mitophagy [262]. In line with the obser-
vation of increased LC3-GFP positive vesicle formation (Figure 22), ectopic expression of
FLAGUBXD1 signiﬁcantly increased (p=0.0029) mitophagy following addition of CCCP.
While 16.8 +/-11.6 % of CCCP treated control cells displayed mitophagy, CCCP treat-
ment triggered mitophagy in 30.8 +/- 9.6 % of FLAGUBXD1-expressing cells (Figure 23).
Expression of FLAGUBXD1 in the absence of CCCP treatment did not result in signiﬁcant
induction of mitophagy.
5.8.2 Diminished levels of UBXD1 promote mitophagy
To further assess whether UBXD1 indeed promotes mitophagy in CCCP treated cells,
HeLa cells with diminished levels of UBXD1 were generated. To this end, CRISPR/Cas9
technology have been employed in this study [263]. An UBXD1 speciﬁc gRNA under
control of the human U6 promoter together with Cas9 and a plasmid containing a ex-
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Figure 24: CRISPR/Cas9-mediated knock down of UBXD1. Using CRISPR/Cas9, UBXD1 was
targeted in HeLa cells and several alleles of UBXD1 were replaced with a reporter cassette coding for
secreted Gaussia luciferase. Shown are schematics of CRISPR/Cas9 strategy (A), PCR analysis of
reporter integration, and levels of UBXD1 in HeLa and HeLaUBXD1-low (western blot, anti-UBXD1).
pression cassette for secreted Gaussia luciferase reporter ﬂanked by UBXD1 sequences
(Figure 24A) was transfected into HeLa cells. Following single cloning by dilution, lu-
ciferase activity was measured in the cell culture supernatant to identify cell clones with
a potential deletion of UBXD1. Luciferase-positive single cell clones were expanded and
integration of the Gaussia reporter in the UBXD1 as veriﬁed by PCR. In addition, de-
tection of UBXD1 levels by Western blotting was performed. As shown in Figure 24B
and C, PCR and Western blot analysis conﬁrmed correct targeting of UBXD1 and an
about 80 % knockdown of UBXD1 protein levels. Interestingly, no complete knock-out
of UBXD1 could be identiﬁed.
These HeLa cells with diminished levels of UBXD1 were used to assess the impact of
UBXD1 on mitophagic ﬂux. To this end, HeLa and HeLaUBXD1-low cells were transfected
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with mKeima-T2A-3xmycParkin and treated with 10, 25 or 50 µM CCCP for 12 h before
ﬂow cytometric analysis. As shown in Figure 25, diminished levels of UBXD1 resulted in
blunted mitophagic ﬂux compared to wildtype control cells. While treatment of wildtype
HeLa cells with 10, 25, or 50 µM CCCP resulted in 23.2 ± 16.3, 36.8 ± 9.6 and 29.9 ± 11.1
% mitophagic cells, respectively, the percentage of mitophagic HeLaUBXD1-low cells was
signiﬁcantly reduced by at least 50 % (10 µM: 10.1 ± 2.7, 25 µM: 12.8 ± 5.8, 50 µM 10.7
± 2.8 %). This observation suggests that UBXD1 acts in a pro-mitophagic fashion with
lowered levels of UBXD1 causing a diminished mitophagic ﬂux. This is in line with the
observation of increased mitophagic ﬂux following ectopic expression of UBXD1 (Figure
23).
5.9 The UBXD1-interacting DUB YOD1
Papadopoulos and collegues reported about the DUB YOD1 which in collaboration with
p97 and UBXD1 causes the clearance of ruptured lysosomes through lysophay [186]. Also
YOD1 was shown to be involved in protein dislocation of proteins from the ER driven by
p97 during ERAD [111]. Thus is seems conceivable, that YOD1 is not only involved in
lysophagy and ERAD, but might also play a role in p97-dependent mitophagic processes.
5.9.1 YOD1 isoforms characterization
YOD1 belongs to the DUB subfamily characterized by an OTU domain [264]. Interest-
ingly, alternative splicing of the YOD1 gene results in two transcript variants. Protein
domain structure analysis using InterPro [265] revealed the presence of an UBX, an OTU
and a zinc ﬁnger domain in both isoforms (Figure 26). Due to the alternative splicing,
the N-terminally located UBX domain diﬀers in both isoforms. As the UBX domain is
involved in protein-protein interactions, both YOD1 isoforms - YOD1.1 and YOD1.2 -
were further analyzed.
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Figure 25: UBXD1 is a positive regulator of mitophagy.HeLa cells and HeLaUBXD1-low transfected
with mKeima-T2A-3xmycParkin were treated for 12 h with 10, 25 or 50 µM CCCP or left untreated
as controls and were analyzed by ﬂow cytometry. Shown are representative density plots. The box
plot represents 5 independent experiments. Statistical signiﬁcance was assessed by ANOVA followed
by Student's t-test using correction to account for multiple comparisons according to Holm. * marks
p-values < 0.05, ** < 0.01.
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Figure 26: Domain structure of YOD1. Both YOD1 isoforms contain with UBX, OTU and Zn
three protein-protein interaction domains. YOD1 isoform 2 has a distinct N-terminus and is shorter
compared to isoform 1.
5.9.2 Physical interaction of YOD1 with UBXD1 and p97
To better characterize the two YOD1 isoforms in terms of their ability to interact with
p97 and UBXD1, yeast two hybrid was employed. For that, a serial dilution of yeast
strains containing GAL4BD-YOD1.1 or GAL4BD-YOD1.2 as bait and GAL4AD-p97 or
GAL4AD-UBXD1 as prey was performed. Yeast strains containing GAL4BD-YOD1.1
and GAL4AD-p97 or GAL4AD-UBXD1 showed growth on plates selective for yeast two
hybrid interaction consistent with a direct physical interaction between YOD1.1 and
p97 or UBXD1. However, yeast strains containing GAL4BD-YOD1.2 grew only in the
presence of GAL4AD-UBXD1, but not in the presence of GAL4AD-p97 indicative for a
direct physical interaction between YOD1.2 with UBXD1 but not p97 (Figure 27). Thus,
diﬀerences in the UBX domain between YOD1 isoform 1 and isoform 2 might contribute
to a diﬀerential interaction pattern with p97.
5.9.3 Mitochondrial transloction of YOD1 during mitophagy
HeLa cells co-transfected with expression of mitoYPF-T2A-3xmycParkin and
mcherryYOD1.1 (Figure 28A) and mcherryYOD1.2 (Figure 28B) were treated with
CCCP for 6 h to induce mitophagy. As shown in Figure 28 upon confocal microscopy
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Figure 27: Physical interaction of YOD1 with p97 and UBXD1. Cells of yeast strain Y2HGold were
transformed with expression constructs for fusion proteins between YOD1 isoform 1 and isoform 2 and
the GAL4 DNA binding domain and p97 or UBXD1 and the GAL4 activation domain. Transformation
with pGADT7 (empty vector with GAL4 activation domain  labeled vector) served as control. Yeast
strains were serially diluted onto plates selecting for expression plasmids (control) and plates selecting
for yeast two-hybrid interaction (drop-out).
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analysis of both isoforms, only isoform 2 translocate to CCCP uncoupled mitochondria.
However, this translocation was only observed in a small subset of cells.
5.9.4 YOD1.2 translocates to depolarized mitochondria in a UBXD1 and
Parkin dependent manner
As YOD1.2 and UBXD1 physically interact, the dependence of mitochondrial transloca-
tion of YOD1.2 during mitophagic conditions on UBXD1 was assessed. To this end, HeLa
cells co-transfected with expression plasmids for FLAGUBXD1, mitoYPF-T2A-3xmycParkin
and mcherryYOD1.2 were treated with 50 µM CCCP for 0 to 6 h. As shown in Figure 29,
cells expressing mitoYPF-T2A-3xmycParkin together with FLAGUBXD1 and YOD1.2 re-
vealed YOD1.2 mitochondrial translocation after 6 h of CCCP treatment when UBXD1
is found in the cytosol. UBXD1 is found on mitochondria after 6 h of CCCP treatment
when YOD1.2 is cytosolic and does not co-localize with either UBXD1 or mitoYPF-
T2A-3xmycParkin. These observations are consistent with UBXD1 recognizing depolar-
ized, Parkin-containing mitochondria followed by increased recruitment of YOD1.2. The
exclusive mitochondrial localization of UBXD1 and YOD1.2 under mitophagic conditions
hints to a multi-step process where UBXD1 recognizes damaged mitochondria, recruits
p97 and YOD1.2 and is released back into the cytosol.
5.9.5 Domain organization of YOD1.2 and its mutant derivatives
To study the role of the diﬀerent protein domains in YOD1.2 and their impact on mito-
chondrial translocation, a variant lacking the N-terminal UBX and the OTU domain were
generated (Figure 30).
5.9.6 Domain requirement for YOD1.2 mitochondrial translocation
HeLa cells co-expressing FLAGUBXD1 and mcherryYOD1.2 lacking UBX or OTU domain
together with mitoYFP-T2A-3xmycParkin were treated with CCCP or left untreated. As
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Figure 28: YOD1.2 translocates to depolarized mitochondria in a Parkin-dependent manner. HeLa
cells transfected with YOD1 isoform 1 (A) or isoform 2 (B) and mitoYPF-T2A-3xmycParkin were
treated for 6 h with 50 µM CCCP, ﬁxed and analyzed by ﬂuorescence microscopy. Shown are
representative images of three independent experiments.
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Figure 29: UBXD1 enhances mitochondrial translocation of YOD1.2. HeLa cells transfected with
YOD1.2 isoform and mitoYPF-T2A-3xmycParkin were treated for 6 h with 50 µM CCCP, ﬁxed, stained
using mouse anti-Flag antibodies to detect FLAGUBXD1 and analyzed by ﬂuorescence microscopy.
Shown are representative images of two independent experiments.
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Figure 30: Schematic domain organization of YOD1.2 and YOD1.2 mutants. YOD1 contains with
UBX, OTU and Zn three protein-protein interaction domains. Shown are drawn to scale schematic
representation of YOD1 truncation mutants used in this study
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shown in Figure 31A, YOD1.2 lacking UBX, or lacking UBX and OTU (Figure 31B,C)
were not capable of mitochondrial translocation in UBXD1 dependent manner. This data
suggests that the UBX domain of YOD1.2 is critical for its mitochondrial translocation.
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Figure 31: UBX (A) and Zn domains (B+C) are essential for YOD1.2 mitochondrial translocation.
HeLa cells transfected with expression plasmids for FLAGUBXD1 or variants of YOD1.2 and mitoYFP-
T2A-3xmycParkin were treated with CCCP for 6 h or left untreated as control. Fixed cells were stained
using mouse anti-FLAG antibodies and analyzed by confocal microscopy. Shown are representative
images of two independent experiments.
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6 Discussion
Mitochondrial dysfunction is central to virtually all neurodegenerative processes [266],
with mitochondrial failure as consequence of accumulating damage to mitochondrial com-
ponents over time. Therefore multiple mitochondrial quality control mechanisms are an
essential part of maintaining cellular function to prevent aging and untimely death of
neuronal cells. Keeping mitochondria in a healthy state is a complex process and has
to be tightly regulated [267]. The aim of this work was to better understand the inter-
play between mitochondrial maintenance and the ubiquitin proteasome system with a
special focus on p97 and its cofactors. The work presented here further establishes the
role of p97 in mitochondrial quality control through mitophagic clearance of uncoupled
mitochondria. Also, with UBXD1, YOD1.2, SAKS1 and Erasin, four novel partners for
mitochondrial functions of p97 were identiﬁed and UBXD1 and YOD1 were characterized
in more detail.
6.1 UBXD1 as mitochondrial recruitment factor for p97
UBXD1 contains with PUB and VIM two distinct p97 binding domains, enabling it
to interact with p97 in a bipartite manner [268]. According to the literature [158],
the N-terminal VIM and PUB domain are both suﬃcient to bind p97. Interestingly,
upon ectopic expression, both domains are individually capable of recruiting p97 to
mitochondria under mitophagic conditions. Based on results from quantitative yeast
two-hybrid (Figure 21), both domains might provide additive binding strength. These
observations point to additional functions of the bipartite, VIM/PUB-containing p97
binding motif in UBXD1. As suggested by Kern [183], VIM and PUB domain likely bind
to diﬀerent regions of p97 [183]. In accordance with our yeast-2-hybrid interaction data,
this leads to a stronger binding between p97 and UBXD1. However, also a regulatory
function for this binding pattern might be considered. It is conceivable, that UBXD1 not
only recruits p97 via its VIM and PUB domain to mitochondria, but also regulates p97
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activity additionally. Kern and colleagues [183] identiﬁed the VIM as direct competitor
for binding between p97 and its cofactor p47. Whether such a mechanism is also involved
in the mitophagy-related function of UBXD1 is unclear. While, p47 was connected to
ER and Golgi biogenesis [269], no mitochondrial function for p47 is established until
now. Nonetheless, that the bipartite p97 interaction motif consisting of the VIM and
PUB domain might serve similar functions during mitophagy and not only recruits
p97 to mitochondria but might also adjust cofactor binding of p97 under mitophagic
conditions.
As for the UBX domain found in UBXD1, our data are consistent with UBXD1 recogniz-
ing depolarized mitochondria undergoing Parkin-dependent mitophagy and facilitating
p97 recruitment. As shown in Figure 15, recognition of mitophagic mitochondria depends
exclusively on the UBX domain contained in UBXD1, as evidenced by the complete lack
of mitochondrial translocation of UBXD1 missing its UBX domain. The UBX domain
does not contribute to p97 binding, although the UBX domain is generally considered
to be a p97 interaction motif [270]. Our data points to a role for the UBX domain of
UBXD1 as receptor for mitochondria undergoing mitophagy. It remains unclear what
mitochondrial signal triggers UBXD1 translocation, however, it is likely that the UBX
domain of UBXD1 recognizes a factor only present on mitochondria after mitophagic
induction. A yeast-two-hybrid screen using the UBX domain of UBXD1 as bait and
a cDNA library from CCCP-treated HeLa cells as prey did not reveal proteins with
mitochondrial localization in mitophagic cells (Neutzner, personal communication).
Bringing UBXD1 fused to the ActA tail to mitochondria in the absence of Parkin and
CCCP resulted in the recruitment of p97 (Figure 19). This suggests that UBXD1 is
suﬃcient for p97 to recognize mitophagic mitochondria and additional signals are not
necessary for this particular process. This observation further supports the notion that
UBXD1 bridges mitochondria undergoing mitophagy with p97 and subsequently with
the UPS.
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6.2 Multiple connections between p97 and mitochondria
The work presented here strongly connects p97 via UBXD1 and potentially YOD1.2 to
mitochondrial quality control. The identiﬁcation of other p97 cofactors, namely SAKS1
and Erasin, hints to potentially additional roles for p97 in mitochondrial health. Depolar-
ization of mitochondria in Parkin-expressing cells triggers likely a plethora of mechanisms
all with the goal of removing mitochondrial subunits. With mitophagy being highly reg-
ulated and the general importance of ubiquitination, it is likely that several regulatory
modules are in need for p97-mediated processing of ubiquitinated proteins. Also the diﬀer-
ent domain composition of the newly identiﬁed p97 cofactors points in the same direction.
Especially interesting in this regard is Erasin. This cofactor contains a transmembrane
domain anchoring the protein in the ER membrane. Upon mitophagic induction, Erasin
seems to migrate towards ER-mitochondria contact sites (Neutzner, personal communica-
tion) suggesting a role for p97 at this important inter-organellar nexus during mitophagy.
While further work is necessary to deﬁne the function of SAKS1, Erasin and YOD1.2, the
identiﬁcation of four novel accessory p97 proteins translocating to mitochondria under
mitophagic conditions suggests an even more intricate relationship between the UPS and
mitochondria as previously appreciated.
6.3 UBXD1 as pro-mitophagic factor
The translocation of UBXD1 after mitochondrial depolarization strongly suggests a
role during mitophagy. Since p97 acts in a pro-mitophagic manner, it is resonable
to expect that also UBXD1 is likely a pro-mitophagic factor. And indeed, ectopic
expression of UBXD1 caused an increase in LC3-containing vesicles near mitochondria
consistent with a positive regulatory function. In line with this observation, a signiﬁcant
decrease of mitophagy was observed in HeLaUBXD1-low cells (Figure 25). Increased
mitophagy following ectopic expression of UBXD1 and decreased mitophagic ﬂux under
conditions of lowered UBXD1 levels are consistent with a pro-mitophagic role. While
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it remains unclear how UBXD1 causes the observed increase in mitophagic ﬂux, it is
likely that removal of certain mitochondrial proteins by UBXD1 together with p97 is
involved. It was previously described that p97-mediated removal of mitofusins promotes
mitophagy. [255]. Interestingly, UBXD1 in concert with p97 and other cofactors was
recently shown to promote the removal of K48-linked ubiquitin from ruptured lysosomes,
thereby increasing the amount of K63-linked ubiquitin tipping the balance towards
lysophagy. [186]. A similar mechanism might be at work during mitophagy. Here,
Parkin is known to generate not only K48, but also K63-linked as well as other types
of polyubiquitin on mitochondria. In analogy to the role of K48 and K63 ubiquitin
chains in lysophagy, UBXD1 may also modulate the balance between these types of
polyubiquitin on mitochondria promoting mitophagy.
6.4 UBXD1 and YOD1 in mitochondrial quality control
In order to maintain mitochondrial homeostasis, p97-mediated retrotranslocation of mis-
folded proteins is needed likely involving diﬀerent cofactors and potentially deubiquiti-
nating enzymes. Based on our data connecting UBXD1 to OMMAD and reports by
Ernst and colleagues [111], we examined YOD1, an UBX-domain-containing member of
the otubain family of DUBs. According to the literature, YOD1 is a p97-associated deu-
biquitinting enzyme in association with ERAD [102, 111, 271, 272]. A dominant negative
mutant of YOD1 (YOD1C160S) has been shown to stabilize ERAD substrates mostly in
a non-ubiquitinated and glycosylated form. This accumulation of substrate proteins in
the ER lumen might be a consequence of stalling molecules in the putative exit channel
[102, 111]. As for p97-mediated retrotranslocation, deubiquitinating activity of YOD1 is
also required for retrotranslocation [120, 111, 271].
YOD1 comes in two diﬀerent isoforms - YOD1.1 and YOD1.2 - and is part of multipro-
tein complex containing p97 [111]. According to Pfam predictions [273], YOD1 comprises
three domains, an N-terminal UBX domain, OTU domain, and a C-terminal zinc ﬁnger
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domain. Interestingly, the N-terminal UBX domain diﬀers between the two YOD1 iso-
forms. As shown in Figure 29 upon UBXD1 expression both domains, UBX and Zn are
necessary for YOD1.2 mitochondrial recruitment, under mitophagic conditions.
In line with previous reports [186], YOD1 acts as an ubiquitin sensor and together with
UBXD1 drives the clearance of ruptured lysosomes by autophagy. Such a mechanism
might also be in play during mitophagy. Alternatively and based on our time course
experiments (Figure 29), initial recognition of mitophagic mitochondria is performed by
UBXD1 via its UBX domain. Following p97 mitochondrial recruitment through the VIM
and PUB domain of UBXD1, YOD1.2 translocates to this complex. Based on our ﬁnd-
ings of direct interaction between UBXD1 and both isoforms of YOD1 and the diﬀerential
interaction between p97 and YOD1 isoforms (Figure 27), mitochondrial translocation of
YOD1.2 is likely triggered by binding to UBXD1 on mitochondria. Interestingly, YOD1.2
shows only very limited recruitment to mitophagic mitochondria in the absence of ectopi-
cally expressed UBXD1, and UBXD1 and YOD1.2 are not found on the same mito-
chondria together. This might be explained by a two-step mechanism. Upon recognition
of mitophagic mitochondria by UBXD1 and YOD1.2 recruitment, the presence of YOD1.2
triggers the next step in the UBXD1-mediated mitophagic process. Due to the presence
of DUB activity in YOD1.2 it is tempting to speculate that ubiquitinated mitochondrial
proteins are deubiquitinated. The consequence of this hypothesized deubiquitination
could be two-fold. Either mitophagy is damped by counteracting Parkin-mediated ubiq-
uitination, or mitophagy might also be accelerated due to diminishing K48 and enriching
K63 ubiquitination of mitochondria as observed during lysophagy [186]. Further work
will be necessary to address these questions.
6.5 Potential connections between UBXD1 and neurodegenera-
tive disease
Mutations in p97 are connected to the development of IBMPFD. Such disease-causing
mutations of p97 were shown to alter interaction with UBXD1 connecting this cofactor
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to a disease process [274]. Mutations in p97 causing myopathy and neurodegeneration
were shown to hamper interaction with UBXD1, resulting in impaired degradation and
subsequent accumulation of p97 client proteins [185]. Also, UBXD1 was recently con-
nected to the degradation of mitochondrial MCL1 in the context of an in vitro model
of Huntington's disease. [274]. Since impaired mitophagy is strongly linked to neurode-
generative diseases, it is tempting to speculate that, due to altered binding of mutant
p97 to UBXD1, p97-linked myopathy and neurodegeneration might not only be a conse-
quence of disrupted lysophagy, but might also result from impaired mitophagic clearance
of damaged mitochondria.
6.6 Organelle-linked ubiquitination shares p97-mediated retro-
translocation
Ubiquitination plays an essential role in virtually all cellular processes, and especially
in the quality control of proteins. Recently, the role of ubiquitination and ubiquitin-
dependent protein degradation in mitochondrial physiology became clearer. For OM-
MAD, the special topology of mitochondria requires specialized protein degradation
mechanisms. As the UPS is mainly cytosolic, ubiquitin-dependent degradation of mito-
chondrial proteins necessitates the presence of factors able to connect the UPS to mito-
chondria. OMM-anchored RING ﬁnger ubiquitin ligases such as MARCH5 [253], MU-
LAN/MAPL [275] and IBRDC2 [191] might provide this interfacing function with the help
of p97 [276, 277] and its cofactors. This is similar to (ERAD) [278]. There too, membrane-
anchored ubiquitin ligases target organelle-resident proteins for proteasomal degradation,
and there too, p97 and its cofactors are involved in the retrotranslocation of ubiquiti-
nated protein. Interestingly, while both processes employ a diﬀerent set of ubiquitin
ligases relying on diﬀerent mechanisms for selecting substrate proteins for ubiquitination,
p97 seems to be a common component of OMMAD and ERAD linking organelle-speciﬁc
recognition and ubiquitination to the shared downstream degradation machinery. Also for
lysophagy, p97-mediated retrotranslocation of ubiquitinated proteins aids the autophagic
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process [184, 185, 186, 274]. These mechanisms do not only share p97, but also cofactors.
In this study, the recruitment of UBXD1 and YOD1.2 to mitochondria was established.
Interestingly, both p97 cofactors are also connected to ERAD and lysophagy. Although
protein retrotranslocation from lysosomes, mitochondria, and the ER certainly serves
diﬀerent functions and a varied machinery is involved in substrate targeting, p97 and to
some extent its cofactors are a common theme in ubiquitin-dependent organellar quality
control pathways.
6.7 UBXD1 linking UPS and mitophagy
Under physiological conditions, mitochondria are exposed to diﬀerent stressors leading
to diﬀerent levels of damage. While initial low level damage is likely dealt with OM-
MAD through the removal of ubiquitinated proteins from mitochondria, mitophagic pro-
cesses come in play once more extensive damage accumulates despite OMMAD activity.
Our data supports a new role for p97-retrotranslocation mechanism in association with
UBXD1 (Figure 32). In addition, our ﬁndings may connect the potential OMMAD mech-
anism with the clearance of damaged mitochondria through mitophagy. OMMAD may
therefore provide an initial mitochondrial quality control for the clearance of misfolded
proteins and help to keep mitochondria in a healthy state during constant low level of
stress conditions. However, if mitochondrial damage levels exceed the capacity of OM-
MAD, mitophagic processes are initiated. P97 together with UBXD1 and YOD1.2 might
be part of the regulatory mechanisms helping to switch from OMMAD to mitophagic
quality control mechanisms. Thus, UBXD1 might role for the UPS in the maintenance
of mitochondrial homeostasis by regulating organelle dynamics, the proteasome and mi-
tophagy.
94
Figure 32: Model of UBXD1 in modulating the mitochondria quality control. Polyubiquitination of
mitochondrial proteins by the catalyzed reaction of E1, E2 and E3 enzymes in this depiction leads
to the recruitment of the P97/VCP complex by UBXD1 to the OMM. P97/VCP can extract an
ubiquitinated protein in an ATP-dependent process that facilitates its proteasomal degradation with
the help of DUBs such YOD1. On the other hand, the UPS is also needed for the autophagic
degradation of damaged mitochondria, a process known as mitophagy.
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 Temos, todos que vivemos,
Uma vida que é vivida
E outra vida que é pensada,
E a única vida que temos
É essa que é dividida
Entre a verdadeira e a errada.
Qual porém é a verdadeira
E qual errada, ninguém
Nos saberá explicar;
E vivemos de maneira
Que a vida que a gente tem
É a que tem que pensar. FP
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